

## CONTENTS

PREFACE	xi
Embryonic Stem Cells Provide a Powerful and Versatile Model System	
Molecules in Blastocyst Implantation : Uterine and Embryonic Perspectives	
Microarray Analysis of B-Cell Stimulation	
Tissue Culture Models for Studies of Hormone and Vitamin Action in Bone Cells	
Transport of Leukotriene C <sub>4</sub> and Structurally Related Conjugates	
Interleukin -1 $\beta$ Exerts a Myriad of Effects in the Brain and in Particular in the Hippocampus :	
Analysis of Some of These Actions	
Leptin and Sweet Taste	
Molecular, Structural, and Cellular Biology of Follitropin and Follitropin Receptor	
Factor VIIa/Tissue Factor-Induced Signaling : A Link Between Clotting and Disease	
Antiproliferative Action of Vitamin D	

## CONTENTS

Contributors	xv
Preface	xix
1 Molecular Biology of Hematopoietic Stem Cells	
2 Aldosterone : Its Receptor, Target Genes, and Actions	
3 Corticosteroid Receptors, 11 $\beta$ -Hydroxysteroid Dehydrogenase, and the Heart	
4 Forms of Mineralocorticoid Hypertension	
5 Peroxisome Proliferator-Activated Receptors and the Cardiovascular System	
6 Serotonin and the Neuroendocrine Regulation of the Hypothalamic-pituitary- Adrenal Axis in the Health and Disease	
7 The Thymosins Prothymosin $\alpha$ , Parathymosin, And $\beta$ -Thymosin : Structure and Function	
8 Thymosin $\beta_4$ Interactions	
9 Polypeptide Hormones : Signaling Molecules in Plants	
10 Parathyroid Hormone-Related Protein (PTHrP) : A Nucleocytoplasmic Shuttling Protein with Distinct Paracrine and Intracrine Roles	
11 Nerve Growth Factor-Dependent Regulation of Nade-Induced Apoptosis	
12 Membrane Transport of Folates	
13 Vitamin A and Infancy : Biochemical, Functional, and Clinical Aspects	
Index	593

## CONTENTS

<b>1. Specificity of Molecular Recognition Learned from the Crystal Structures of Trail and the TRAIL: SDR5 Complex</b>	
I. Introduction: The and TNF Receptor Superfamilies	2
II. TRAIL and its Receptors	3
III. Selective Antitumor Activity and Biologic Functions of TRAIL	4
IV. Overall Structure of TRAIL	5
V. Zinc Binding and its Critical Role	5
VI. Unique Frame Insertion in the AA' Loop	8
VII. Structure of TRAIL: sDR5 Complex	9
VIII. Determinants Conferring Specificity of Receptor Recognition	12
IX. Conclusions and Perspectives	13
<b>2. Crystal Structure of Rank Ligand Involved in Bone Metabolism</b>	
I. Introduction	20
II. The OPG/RANKL/RANK System	21
III. Three-Dimensional Structure of PANKL	25
IV. Conclusion	29
<b>3. Promoter of Trail-R2 Gene</b>	
I. Introduction	36
II. Basic Structure of TRAIL-R2 Promoter	37
III. Regulator of TRAIL-R2	40
IV. Possibility of Cancer Therapy Using TRAIL-R2	43
<b>4. Transcriptional Regulation of the Trail-R3 Gene</b>	
I. Introduction: TRAIL and its Receptors	52
II. Decoy Receptors	54
III. TRAIL-R3	56
IV. Future Directions	60
<b>5. Monoclonal Antibodies Against Trail</b>	
I. Introduction	66
II. Overview of monoclonal Antibodies Against TRAIL	67
III. Applications of Monoclonal Antibodies Against TRAIL	70
IV. Physiologic Significance of TRAIL	74
V. Future Aspects	76
<b>6. Modulation of Trail Signaling Complex</b>	
I. TRAIL: A New Member of TNF Family	82
II. TRAIL Death Receptors: DR4 and DR5	83
III. TRAIL Decoy Receptors: DR4, DcR2, and OPG	84

IV. TRAIL-Induced DISC: Cleavage of Apoptosis Initiating Protease Caspase-8	85
V. TRAIL-Induced Bid Cleavage: Activation of Mitochondrial Pathways	87
VI. TRAIL-Induced Cell Proliferation: RIP-Mediated NF-kB Activation	87
VII. TRAIL-Induced c-FLIP Recruitment: DISC Modulation	88
VIII. TRAIL-Induced PED Recruitment: Differential Modulation of the DISC	90
IX. TRAIL Physiologic Functions: Tumor Surveillance	91
X. Recombinant TRAIL: A Novel Cancer Therapeutic Agent	91
<b>7. Trail and NF kB Signaling-A Complex Relationship</b>	
I. Introduction	102
II. Regulation of TRAIL-Induced Apoptosis by NF kB	113
III. TRAIL Activates NF kB	119
<b>8. Cardinal Roles in Apoptosis and NF kB Activation</b>	
I. Introduction	134
II. Regulation of NF kB Activation	134
III. CARD Proteins	135
IV. CARD Proteins and NF kB Activation	135
V. Functions of CARDINAL	138
VI. CARDINAL as a Negative Regulator of Diverse NF kB Activation Pathways	138
VII. CARDINAL and Apoptosis	140
VIII. CARDINAL and Caspase-1 Activation	140
IX. The Inflammasome	141
X. CARDINAL Contradictions	142
XI. Conclusions	143
<b>9. Trail in the Airways</b>	
I. Introduction	150
II. TRAIL: Synthetic and Signaling Pathways	150
III. Effects of TRAIL in the Airways	153
IV. Conclusions	162
<b>10. TRAIL Death Receptors, BCL-2 Protein Family, and Endoplasmic Reticulum Calcium Pool</b>	
I. Introduction	170
II. The Endoplasmic Reticulum	170
III. Endoplasmic Reticulum Ca <sup>2+</sup> Pools and Regulation of Apoptosis	172
IV. Concluding Remarks	183
<b>11. Flip Protein and Trail-Induced Apoptosis</b>	
I. Introduction	190
II. FLIP: Structure and Mechanisms of Action	190
III. FLIP Function in Normal Physiology and Disease	194
IV. TRAIL and FLIP	197
<b>12. Epidermal Growth Factor and Trail Interactions in Epithelial-Derived Cells</b>	
I. Epidermal Growth Factor Receptor-Mediated Cell Survival	208

II. Epidermal Growth Factor Signaling Pathways	209
III. Transcriptional Activation	213
IV. Antiapoptotic Proteins	214
V. Targeting Epidermal Growth Factor Receptor Signaling for Treatment of Cancer	216
VI. TRAIL Death Receptors	217
VII. TRAIL as a Cancer Treatment	218
VIII. Convergence of the Epidermal Growth Factor and TRAIL Signaling Pathways	219
<b>13. Trail and Ceramide</b>	
I. Introduction	230
II. TRAIL	231
III. Sphingolipids	234
IV. TRAIL and Creamed	243
<b>14. TRAIL and Viral Infection</b>	
I. Introduction	258
II. Apoptosis as a Process of Degradation of Host Cell and Viral Constituents	259
III. Death Receptor/Ligand Systems	260
IV. The Cytotoxic Activity of TRAIL Against Virus-Infected Cells	262
V. Viral Strategies to Circumvent TRAIL-Induced Apoptosis	264
VI. TRAIL in Virus-Induced Immunosuppression	265
VII. Viruses and TRAIL in Malignant Disease	266
VIII. Conclusions	268
<b>15. Modulation of TRAIL Signaling for Cancer Therapy</b>	
I. Introduction	276
II. The Core Apoptotic Machinery	277
III. TRAIL and its Receptors	278
IV. TRAIL Signaling	278
V. Defective TRAIL Signaling in Cancers	279
VI. TRAIL and Cancer Therapy	281
VII. Conclusions	284
<b>16. Interferon-Gamma and TRAIL in Human Breast Tumor Cells</b>	
I. Introduction	292
II. Interferon- $\gamma$	293
III. TRAIL System	297
IV. Regulation by IFN- $\gamma$ of TRAIL-Induced Apoptosis in Breast Tumor Cells	303
V. Conclusions	308
<b>17. Retinoids and TRAIL: Two Cooperating Actors to Fight Against Cancer</b>	
I. Introduction	320
II. Origin of Retinoids	322
III. Mechanism of Retinoid Action	322
IV. Anticancer Activity of Retinoic Acids	325

V. Retinoid Action Human Cancers	328
VI. APO2L/TRAIL and its Receptors	330
VII. Preventive and therapeutic Potential of Retinoids: The TRAIL Connection	334
VIII. Future Directions	336
<b>18. Potential for TRAIL as a Therapeutic agent in Ovarian Cancer</b>	
I. Introduction	348
II. Ovarian Cancer	348
III. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand	351
IV. Interleukin-8	35
V. Role of p38 MAPK in Apoptosis	356
VI. Summary	357
<b>19. TRAIL and Chemotherapeutic Drugs in Cancer Therapy</b>	
I. Introduction	366
II. Receptors for TRAIL	367
III. Signaling Pathways of TRAIL Receptors	368
IV. Bioactivity of TRAIL	369
V. Synergistic Effect of TRAIL and Chemotherapeutic Drugs	372
VI. Molecular Mechanisms of the Synergistic Effect	372
VII. Conclusions and Prospects	376
<b>20. Additive Effects of TRAIL and Paclitaxel on Cancer Cells: Implications for Advances in Cancer Therapy</b>	
I. Introduction	386
II. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand	388
III. Paclitaxel	392
IV. Biologic and Clinical Benefits of TRAIL and Paclitaxel Combination Therapy	397
V. Conclusions	402
<b>21. Regulation of Sensitivity to TRAIL by the Pten Tumor Suppressor</b>	
I. Introduction	411
II. Regulation TRAIL-Induced Apoptosis	411
III. Regulation of the Phosphatidylinositol-3 Kinase Pathway by PTEN	414
IV. Modulation of TRAIL Sensitivity by the Phosphatidylinositol-3 Kinase/PTEN/Akt-Pathway	416
V. Downstream Targets of the Phosphatidylinositol-3 Kinase/PTEN/Akt Pathway	417
VI. Strategies for Overcoming TRAIL Resistance	419
<b>22. TRAIL and Malignant Glioma</b>	
I. Malignant Glioma	428
II. Apoptosis in Cancer	430
III. Apoptosis Pathways Overview	433
IV. TRAIL	435
V. TRAIL and Glioma	437

VI. Future Directions	444
<b>23. Regulation of TRAIL-Induced Apoptosis by Ectopic Expression of Antiapoptotic factors</b>	
I. Introduction	454
II. Negative Regulation of TRAIL-Induced Apoptosis	458
III. Inhibitors of Antiapoptotic Factors as Therapeutic Agents	471
IV. Effect of TRAIL on Normal Cells	473
V. Conclusions	474
<b>Index</b>	<b>485</b>

# CONTENTS

---

CONTRIBUTORS XIII

PREFACE XV

## 1

---

### GENE SILENCING BY NUCLEAR ORPHAN RECEPTORS

YING ZHANG AND MARIA L. DUFAU

- I. Introduction 2
- II. COUP-TFI, II (EAR3, ARP-1), and EAR2: Inhibitors of Diverse Genes by Multiple Mechanisms 7
- III. DAX-1: Silencing in the Control of Steroidogenic and Sex-Determining Target Genes 14
- IV. GCNF: Negative Control during Gametogenesis and Embryonic Development 20
- V. SHP: Generic Heterodimeric Partner-Inhibiting Multiple Nuclear Receptor Pathways 24
- VI. TR4 and TR2: Testicular Receptor with Homologous but Not Redundant Functions 30
- VII. Conclusions 34
- References 35



## 2

### STRUCTURE AND FUNCTION OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN

RANDY K. BLEDSOE, EUGENE L. STEWART, AND KENNETH H. PEARCE

- I. Functional Significance of the GR 51
  - II. Expression, Purification, and Characterization of the GR LBD 55
  - III. Fold of the Nuclear Receptor LBD and Specific Features of GR 59
  - IV. Ligand Recognition by GR 64
  - V. Modes of Ligand Recognition by GR Compared to Other Oxosteroid Receptors 68
  - VI. Characteristics of Cofactor Association with the GR LBD 71
  - VII. Role of the GR LBD in Chaperone Protein Association and Receptor Dimerization 74
  - VIII. Mutations in the GR LBD and Their Functional Consequences 76
  - IX. Progress Toward a Selective GR Modulator 82
  - X. Conclusions and Directions of Future Research 83
- References 84

## 3

### NUCLEAR RECEPTOR RECRUITMENT OF HISTONE-MODIFYING ENZYMES TO TARGET GENE PROMOTERS

CHIH-CHENG TSAI AND JOSEPH D. FONDELL

- I. Overview of Nuclear Receptors 94
  - II. Chromatin Structure 96
  - III. Histone Modifications in Regulated Transcription 98
  - IV. NR Coactivators with Histone-Modifying Activity 103
  - V. NR Corepressors with Histone-Modifying Activity 109
  - VI. Conclusion 114
- References 115

---

## 4

---

### COREPRESSOR RECRUITMENT BY AGONIST-BOUND NUCLEAR RECEPTORS

JOHN H. WHITE, ISABELLE FERNANDES, SYLVIE MADER, AND  
XIANG-JIAO YANG

- I. The Nuclear Receptor Superfamily 124
- II. Coregulatory Proteins in Hormone-Dependent Regulation of Transcription 127
- III. Histone Deacetylases in Regulation of Gene Expression 132
- IV. LCoR and RIP140 Recruit the Corepressor C-Terminal Binding Protein (CtBP) 135
- V. Potential Roles of LCoR and RIP140 in Hormone-Dependent Receptor Function 136
- VI. Concluding Remarks 137
- References 138

---

## 5

---

### PHARMACOLOGY OF NUCLEAR RECEPTOR—COREGULATOR RECOGNITION

RAJESH S. SAVKUR, KELLI S. BRAMLETT, DAVID CLAWSON, AND  
THOMAS P. BURRIS

- I. Introduction 146
- II. Coregulators Involved in Nuclear Receptor Action 150
- III. Nuclear Receptor—Coregulator Recognition 164
- IV. Pharmacology of Nuclear Receptor—Coregulator Recognition 170
- V. Conclusion 173
- References 174

## 6

### THYROID HORMONE RECEPTOR SUBTYPES AND THEIR INTERACTION WITH STEROID RECEPTOR COACTIVATORS

ROY E. WEISS AND HELTON E. RAMOS

- I. Introduction 186
- II. Physiology of TR Function 190
- III. Physiology of SRC Function (SRC-1, SRC-2, and SRC-3) 194
- IV. Interaction of TRs and SRC in the Pituitary 196
- V. SRC-1 and TRs in Peripheral Tissues 200
- VI. Conclusions 202
- References 203

## 7

### COREPRESSOR REQUIREMENT AND THYROID HORMONE RECEPTOR FUNCTION DURING XENOPUS DEVELOPMENT

LAURENT M. SACHS

- I. Introduction 210
- II. Mechanism of TR Action 212
- III. Dual Role of TRs During Amphibian Development 216
- IV. Corepressor Function During Amphibian Development 219
- V. Conclusion and Perspectives 225
- References 226

## 8

### CDC25B AS A STEROID RECEPTOR COACTIVATOR

STEVEN S. CHUA, ZHIQING MA, ELLY NGAN, AND SOPHIA Y. TSAI

- I. Introduction 233
- II. The Cdc25 Family of Proteins 234
- III. Evaluation of the Cdc25B Role in Murine Mammary Glands 236
- IV. Cdc25B: A Coactivator that Enhances Steroid  
Receptor-Dependent Transcription 239

- V. Coactivator Function of Cdc25B in the Prostate 245  
VI. Conclusions 248  
References 252

## 9

### VITAMIN D RECEPTOR—DNA INTERACTIONS

PAUL L. SHAFFER AND DANIEL T. GEWIRTH

- I. Introduction 258  
II. VDR—DR3 Binding 261  
III. Alternative Response Elements 266  
IV. RXR—VDR Formation 269  
V. Conclusions 270  
References 271

INDEX 275

# CONTENTS

---

CONTRIBUTORS XIII

PREFACE XVII

## 1

---

### THE GENOMIC VIEW OF GENES RESPONSIVE TO THE ANTAGONISTIC PHYTOHORMONES, ABSCISIC ACID, AND GIBBERELLIN

JUNSHI YAZAKI AND SHOSHI KIKUCHI

- I. Introduction 2
- II. Comprehensive Analysis of ABA-Responsive Genes  
by Genomics Approach 5
- III. Comprehensive Analysis for GA-Responsive Genes  
by the Genomics Approach 12
- IV. Specificity of Gene Responses to Both Hormones 16
- V. *cis*-Element Analysis 16
- VI. Conclusion and Future Prospects 21
- References 23

## 2

### GRAVITROPIC BENDING AND PLANT HORMONES

SONIA PHILOSOPH-HADAS, HAYA FRIEDMAN, AND SHIMON MEIR

- I. Introduction 32
- II. The Gravitropic Bending of Plants 34
- III. Role of Auxin 36
- IV. Role of Ethylene 50
- V. Role of Gibberellins 56
- VI. Role of Abscisic Acid 58
- VII. Role of Cytokinins 60
- VIII. Role of Brassinosteroids, Jasmonates, and Salicylic Acid 63
- IX. Concluding Remarks and Future Prospects 65
- References 66

## 3

### HORMONAL REGULATION OF SEX EXPRESSION IN PLANTS

SEIJI YAMASAKI, NOBUHARU FUJII, AND HIDEYUKI TAKAHASHI

- I. Introduction 80
- II. Differentiation of Flower Buds and Sex Expression in Maize 82
- III. Genetic and Hormonal Regulation of Sex Expression in Maize 83
- IV. Differentiation of Flower Bud and Sex Expression in Cucumber 87
- V. Hormonal Regulation of Sex Expression in Cucumber 88
- VI. Genetic Regulation of Sex Expression in Cucumber 94
- VII. Environmental Regulation of Sex Expression 96
- VIII. Identity of Floral Organs and Regulation of Sex Expression 97
- IX. Programmed Cell Death and Sex Determination 102
- X. Conclusions 103
- References 104

## 4

### PLANT PEROXISOMES

SHOJI MANO AND MIKIO NISHIMURA

- I. Introduction 112
- II. Discovery, Structure, and Localization in Cells 113
- III. Peroxisome Functions in Higher Plants 114
- IV. Transition of Peroxisome Function 122
- V. Peroxisome Biogenesis 123
- VI. Challenge of Comprehensive Approach in the Postgenomic Era 140
- VII. Few Final Considerations and Perspectives 143
- References 143

## 5

### REGULATORY AND FUNCTIONAL INTERACTIONS OF PLANT GROWTH REGULATORS AND PLANT GLUTATHIONE S-TRANSFERASES (GSTs)

ANN MOONS

- I. Classification, Structure, and Subcellular Localization of Plant GSTs 157
- II. Functions of Plant GSTs 161
- III. The Transcriptional Regulation of GST Gene Expression 174
- IV. Potential Involvement of Plant Growth Regulators in Post-transcriptional Regulations of GST Gene Expression 195
- V. Conclusions 197
- References 198

## 6

### AUXINS

CATHERINE PERROT-RECHENMANN AND RICHARD M. NAPIER

- I. Introduction 204
- II. Generation of IAA 205

- III. Cell Division and Tissue Culture 209
- IV. Transport of IAA: Introduction 210
- V. Embryonic Patterning 215
- VI. Vascular Patterning 215
- VII. Auxin Perception, Receptors, and Signaling 216
- VIII. Organ Patterning 221
- IX. Apical Dominance and Branching 222
- X. Tropisms and Epinasty 222
- XI. Adventitious Rooting and Wound Responses 223
- XII. Fruit Growth 224
- XIII. Herbicides 225
- References 226

## 7

### REGULATORY NETWORKS OF THE PHYTOHORMONE ABSCISIC ACID

ZHEN XIE, PAUL RUAS, AND QINGXI J. SHEN

- I. Introduction 236
- II. Signaling Pathways 238
- III. Cross-talk of ABA and GA 257
- IV. Conclusions 258
- References 259

## 8

### CYTOKININ BIOSYNTHESIS AND REGULATION

HITOSHI SAKAKIBARA

- I. Introduction 272
- II. Structural Variation of Cytokinin 273
- III. Biosynthesis of Cytokinin 275
- IV. Regulation of Cytokinin Biosynthesis in Higher Plants 280
- References 283



---

**9**

---

**GIBBERELLIN METABOLISM  
AND SIGNALING**

STEPHEN G. THOMAS, IVO RIEU, AND CAMILLE M. STEBER

- I. Introduction 290
- II. Gibberellin Biosynthesis 295
- III. Gibberellin Signal Transduction 312
- IV. Cross-talk with Other Hormone-Signaling Pathways 323
- V. Perspectives 326
- References 326

---

**10**

---

**NITRIC OXIDE SIGNALING IN PLANTS**

ALLAN D. SHAPIRO

- I. Introduction 340
- II. Nitric Oxide Biosynthesis 341
- III. NO Metabolism and Transport 350
- IV. NO Function in Plants 358
- V. Conclusions 384
- References 386

---

**11**

---

**ETHYLENE BIOSYNTHESIS AND SIGNALING:  
AN OVERVIEW**

ANNELIES DE PAEPE AND DOMINIQUE VAN DER STRAETEN

- I. Introduction 400
- II. Biosynthesis of Ethylene: Mechanism and Regulation 401
- III. Ethylene Signaling 405

- IV. Transcriptional Regulation of Ethylene Response 417
- V. Cross-talk in Plant Hormone Signaling 419
- VI. Ethylene in Plant Disease Resistance and Abiotic Stresses 421
- VII. Conclusions 422
- References 423

## 12

### JASMONATE: AN OXYLIPIN SIGNAL WITH MANY ROLES IN PLANTS

JOHN BROWSE

- I. Introduction 432
- II. The Biochemistry of Jasmonate Synthesis 433
- III. Jasmonate Signaling in Insect Defense 435
- IV. New Defense Roles and Signal Integration 441
- V. Jasmonate Regulates Reproductive Development 446
- VI. Ubiquitination by SCF<sup>COI1</sup> is an Early and Essential  
Step in Jasmonate Signaling 449
- References 451

## 13

### PLANT SEX PHEROMONES

HIROYUKI SEKIMOTO

- I. Introduction 458
- II. Brown Algal Pheromones 459
- III. The *Volvox* Sex-Inducing Pheromone 460
- IV. The Sex Pheromones of *Closterium* 463
- V. Other Green Algal Pheromones 467
- VI. Spermatozoid Attractant(s) in Mosses 468
- VII. Pheromones in Ferns 469
- VIII. Attractants in the Pollen Tube 470
- IX. Conclusions 472
- References 472

# 14

## PLANT BRASSINOSTEROID HORMONES

TADAO ASAMI, TAKESHI NAKANO, AND SHOZO FUJIOKA

- I. Biosynthesis and Metabolism of Brassinosteroids 480
- II. Signal Transduction of Brassinosteroids 485
- III. Conclusions 498
- References 498

# 15

## TERPENOIDS AS PLANT ANTIOXIDANTS

J. GRABMANN

- I. Introduction 506
- II. Plant Antioxidants 507
- III. Terpenoids 507
- References 529

INDEX 537

# CONTENTS

---

CONTRIBUTORS XI

PREFACE XIII

## 1

---

### HORMONAL CONTROL OF INSECT ECDYSIS: ENDOCRINE CASCADES FOR COORDINATING BEHAVIOR WITH PHYSIOLOGY

JAMES W. TRUMAN

- I. Introduction 2
- II. The Physiology and Behaviors of the Ecdysis Sequence 3
- III. Endocrine and Neuroendocrine Factors Involved in Ecdysis Control 6
- IV. Interaction of Endocrine Signals in Controlling the Behavioral Phases 16
- V. Conclusions 25
- References 26

## 2

### A MOLECULAR GENETIC APPROACH TO THE BIOSYNTHESIS OF THE INSECT STEROID MOLTING HORMONE

LAWRENCE I. GILBERT AND JAMES T. WARREN

- I. Introduction 32
- II. Ecdysteroids 33
- III. Neuropeptide Control of Ecdysteroidogenesis 36
- IV. Subcellular Translocation of Ecdysteroid Intermediates 38
- V. The "Black Box" 39
- VI. Terminal Hydroxylations (From the Diketol to  
20-Hydroxyecdysone) 41
- VII. Epilogue 54
- References 54

## 3

### ECDYSTEROID RECEPTORS AND THEIR APPLICATIONS IN AGRICULTURE AND MEDICINE

SUBBA R. PALLI, ROBERT E. HORMANN, UWE SCHLATTNER, AND  
MARKUS LEZZI

- I. Introduction 60
- II. Ecdysteroid Receptors 61
- III. Applications 78
- IV. Conclusions and Perspectives 91
- References 91

## 4

### LIGAND-BINDING POCKET OF THE ECDYSONE RECEPTOR

ISABELLE M. L. BILLAS AND DINO MORAS

- I. Introduction 102
- II. Sequence Comparison of Invertebrate EcR  
Ligand-Binding Domains 104

- III. Crystal Structures of the EcR Ligand-Binding Domain 105  
IV. Conclusions 124  
References 126

## 5

### NONSTEROIDAL ECDYSONE AGONISTS

YOSHIAKI NAKAGAWA

- I. Introduction 132  
II. Diacylhydrazines 134  
III. Other Nonsteroidal Ecdysone Agonists 160  
IV. Conclusions 161  
References 162

## 6

### JUVENILE HORMONE MOLECULAR ACTIONS AND INTERACTIONS DURING DEVELOPMENT OF DROSOPHILA MELANOGASTER

EDWARD M. BERGER AND EDWARD B. DUBROVSKY

- I. Introduction 176  
II. Hormones and Development 177  
III. Hormones and Reproduction 184  
IV. Molecular Biology of Hormone Action 187  
V. Hormonal Cross-Talk 197  
References 201

---

# 7

---

## INSECT NEUROPEPTIDE AND PEPTIDE HORMONE RECEPTORS: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS

ILSE CLAEYS, JEROEN POELS, GERT SIMONET, VANESSA FRANSSSENS,  
TOM VAN LOY, MATTHIAS B. VAN HIEL, BERT BREUGELMANS, AND  
JOZEF VANDEN BROECK

I. Introduction	218
II. Members of the Rhodopsin (GPCR Class A) Family	222
III. Members of Other 7TM Families	242
IV. Single Transmembrane Receptors	245
V. Emerging Concepts and Future Developments	260
References	265
INDEX	283

# CONTENTS

---

CONTRIBUTORS XVII

PREFACE XXIII

## 1

---

### IL-3, IL-5, AND GM-CSF SIGNALING: CRYSTAL STRUCTURE OF THE HUMAN BETA-COMMON RECEPTOR

JAMES M. MURPHY AND IAN G. YOUNG

- I. Background 2
- II. The Receptor System for IL-3, IL-5, and GM-CSF 3
- III. Structural Features of Class I Cytokine Receptors 3
- IV. The Ligands: IL-3, IL-5, and GM-CSF 6
- V. The Structure of the Human  $\beta_c$  Receptor 8
- VI. Formation and Biological Relevance of the  $\beta_c$  Homodimer 12
- VII. Elucidation of the  $\beta_c$  Functional Epitope 13
- VIII. Interaction of  $\alpha$ -Subunits with GM-CSF, IL-3, and IL-5 15
- IX. Interaction of  $\alpha$ -Subunits with  $\beta_c$  16
- X. The Murine  $\beta_{IL-3}$  Receptor Binds IL-3 via a Functional Epitope Analogous to that of  $\beta_c$  17
- XI. A Model for  $\beta_c$  Receptor Activation 19
- References 24



## 2

### CRYSTAL STRUCTURES AND INHIBITORS OF PROTEINS INVOLVED IN IL-2 RELEASE AND T CELL SIGNALING

KIERON BROWN AND GRAHAM M. T. CHEETHAM

- I. Overview 32
- II. Importance of IL-2 Release by T Cells and Its Role in Human Disease 32
- III. A Paradigm for Blocking IL-2 Release *In Vivo*: Inhibition of Calcineurin Activity by Cyclosporin and FK-506 34
- IV. Molecular Signaling in T Cells: Multiple Opportunities for Therapeutic Intervention 36
- V. Inhibition of Protein Kinases Proximal to the TCR 38
- VI. Interleukin-2 Tyrosine Kinase: A Novel Downstream Target 45
- VII. Conclusions 52
- References 53

## 3

### STRUCTURAL STUDIES OF THE INTERLEUKIN-19 SUBFAMILY OF CYTOKINES

ALEXANDER ZDANOV

- I. Introduction 62
- II. Interferons- $\lambda$  1,2,3 (IFN- $\lambda$ 1, IFN- $\lambda$ 2, and IFN- $\lambda$ 3, or IL-29, IL-28A, and IL-28B) 69
- III. Cytokine/Receptor Complexes 69
- IV. Concluding Remarks 70
- References 71

## 4

### INTERLEUKIN-22 AND ITS CRYSTAL STRUCTURE

RONALDO ALVES PINTO NAGEM, JOSÉ RIBAMAR FERREIRA JÚNIOR, LAURE DUMOUTIER, JEAN-CHRISTOPHE RENAULD, AND IGOR POLIKARPOV

- I. Interleukin-22 Identification and Gene Expression 78
- II. IL-22R1 Identification and Gene Expression 81

- III. Physiological Role of IL-22 83
- IV. IL-22BP: A Decoy Receptor That Regulates IL-22 84
- V. IL-22 Inflammatory System and Disease 86
- VI. IL-22 Tertiary and Quaternary Structure Organization 87
- VII. IL-22 Signaling Complex 89
- References 100

## 5

### CONTROL OF INTERLEUKIN-2 GENE TRANSCRIPTION: A PARADIGM FOR INDUCIBLE, TISSUE-SPECIFIC GENE EXPRESSION

KAREN BUNTING, JUN WANG, AND M. FRANCES SHANNON

- I. Interleukin-2: Diverse Roles in Immunity  
and Pathogenesis 106
- II. *IL-2*: An Example of a T Cell-Restricted Inducible Gene 109
- III. Genomic Regions That Control *IL-2* Gene Transcription 110
- IV. T Cell Lineage Specificity of *IL-2* Gene Expression 113
- V. The Role of Chromatin in Controlling *IL-2*  
Gene Transcription 115
- VI. Multiple Signals Are Required for Activation of *IL-2*  
Gene Transcription 118
- VII. Mechanisms to Repress the *IL-2* Gene in T Cells 127
- VIII. Conclusions 133
- References 134

## 6

### TRANSCRIPTION FACTORS MEDIATING INTERLEUKIN-3 SURVIVAL SIGNALS

JEFFREY JONG-YOUNG YEN AND HSIN-FANG YANG-YEN

- I. Introduction 148
- II. Mammalian Orthologs of *C. elegans* *Ces2/Ces1*  
Proteins 150
- III. Regulatory Machinery of the *mcl-1* Gene 154
- IV. Discussions 156
- References 159

## 7

### INTERLEUKINS AND STAT SIGNALING

S. JAHARUL HAQUE AND PANKAJ SHARMA

- I. Interleukins: Structure, Classification, and Mode of Action 166
- II. Cytokine Receptors: Structure and Classification 168
- III. Functional Cytokine-Receptor Complexes 170
- IV. Sharing of Receptor-Subunits by Cytokines 171
- V. JAKs: Cytokine Receptor-Associated Protein Tyrosine Kinases 173
- VI. Signal Transducers and Activators of Transcription 176
- VII. Mechanism of JAK-STAT Signal Transduction 180
- VIII. Specificity of Cytokine Signaling 183
- IX. Homeostatic Control of Cytokine Production and Cytokine Signaling 184
- X. Regulation of Cytokine Synthesis 184
- XI. Negative Regulation of Cytokine Signaling 185
- XII. STATs in Human Diseases 189
- XIII. Perspective 192
- References 193

## 8

### THE NEWEST INTERLEUKINS: RECENT ADDITIONS TO THE EVER-GROWING CYTOKINE FAMILY

QIAN CHEN, HELEN P. CARROLL, AND MASSIMO GADINA

- I. The New Interleukins 208
- II. Conclusions 224
- References 224

## 9

### THE INTERLEUKIN-1 RECEPTOR FAMILY

DIANA BORASCHI AND ALDO TAGLIABUE

- I. Introduction 230
- II. IL-1 Receptors 237
- III. IL-18 Receptors 240
- IV. Receptors That Downregulate Signaling 242

- V. Other IL-1R-Like Receptors 244  
VI. Conclusions 245  
References 247

## 10

### THE IL-17 CYTOKINE FAMILY

SARAH L. GAFFEN, JILL M. KRAMER, JEFFREY J. YU, AND FANG SHEN

- I. Overview of the IL-17 Family 256  
II. Molecular and Structural Aspects of the IL-17 Family 257  
III. IL-17A *In Vivo* 262  
IV. Gene Targets and Signal Transduction 268  
V. Concluding Remarks 273  
References 274

## 11

### NF- $\kappa$ B AND CYTOKINES

DAGMAR KULMS AND THOMAS SCHWARZ

- I. The Cytokine Family 284  
II. Nuclear Factor- $\kappa$ B 285  
III. NF- $\kappa$ B/Rel Family Members 286  
IV. Immune Development, Inflammatory Response, and Disease 288  
V. Cytokines and NF- $\kappa$ B in Tumorigenesis and Apoptosis 291  
VI. Conclusions 296  
References 296

## 12

### I $\kappa$ B- $\zeta$ : AN INDUCIBLE REGULATOR OF NUCLEAR FACTOR- $\kappa$ B

TATSUSHI MUTA

- I. Introduction 302  
II. Structure of I $\kappa$ B- $\zeta$  303  
III. Induction of I $\kappa$ B- $\zeta$  by Stimulation of the Innate  
Immune System 304

- IV. Molecular Functions of  $I\kappa B-\zeta$  305
- V. Physiological Roles for  $I\kappa B-\zeta$  308
- VI. Mechanisms of the Induction of  $I\kappa B-\zeta$  310
- VII. Conclusions 312
- References 315

## 13

### THE INHIBITORY EFFECTS OF INTERLEUKIN-1 ON GROWTH HORMONE ACTION DURING CATABOLIC ILLNESS

ROBERT N. COONEY AND MARGARET SHUMATE

- I. Introduction 318
- II. The Interleukin-1 Family 319
- III. Regulation of IL-1 Synthesis 320
- IV. IL-1 Bioactivity: Receptors and Cell Signaling 321
- V. Biologic Activities of IL-1 322
- VI. IL-1 in Disease 322
- VII. IL-1 and Protein Catabolism 323
- VIII. Growth Hormone: Physiologic and Metabolic Activities 323
- IX. Catabolic Illness and GH Resistance 326
- X. GHR Expression in GH Resistance 327
- XI. Hepatic GH Signaling via the JAK2/STAT5 Pathway 328
- XII. GH Signaling by p38/c-Jun/MAPK Pathways 329
- XIII. Suppressors of Cytokine Signaling: Inhibitors of JAK/STAT Signaling 330
- XIV. Inhibition of GH-Inducible Gene Expression by Cytokines (IL-1) 331
- XV. Conclusions 332
- References 333

## 14

### THE ROLE OF THE INTERLEUKIN-6/GP130 SIGNALING PATHWAY IN BONE METABOLISM

XIN-HUA LIU, ALEXANDER KIRSCHENBAUM, SHEN YAO, AND ALICE C. LEVINE

- I. Introduction 342
- II. Effect of IL-6 on Bone Resorption 342

- III. Effect of IL-6 on Bone Formation 344
- IV. Interactions Between IL-6/gp130 Signaling and the OPG/RANKL/RANK System 345
- V. Cross Talk Between IL-6 and Steroid Hormones, PTH, PGE<sub>2</sub>, and Cytokines 346
- VI. gp130 Signaling and Bone Remodeling 350
- VII. Summary 350
- References 351

## 15

### REGULATION OF OSTEOCLAST DIFFERENTIATION AND FUNCTION BY INTERLEUKIN-1

ICHIRO NAKAMURA AND EIJIRO JIMI

- I. Introduction 358
- II. Interleukin-1 and Osteoclast Differentiation 359
- III. Interleukin-1 and Osteoclast Activation 360
- IV. Interleukin-1 and Osteoclast Survival 364
- V. Interleukin-1 and Rheumatoid Arthritis 365
- VI. Prospects 366
- References 366

## 16

### THE ROLE OF IL-1 AND IL-1RA IN JOINT INFLAMMATION AND CARTILAGE DEGRADATION

CLAIRE JACQUES, MARJOLAINE GOSSET, FRANCIS BERENBAUM,  
AND CEM GABAY

- I. Introduction 372
- II. IL-1 and IL-1 Receptors 373
- III. Role of IL-1 and IL-1Ra in Articular Inflammation 378
- IV. Role of IL-1 in Cartilage Breakdown 383
- V. The Role of the Balance Between Endogenous IL-1 and IL-1Ra 386
- VI. Targeting IL-1 in the Treatment of Rheumatic Diseases 387
- VII. Conclusions 391
- References 391

# 17

## CYTOKINES IN TYPE 2 DIABETES

DANIEL R. JOHNSON, JASON C. O'CONNOR, ANSUMAN SATPATHY,  
AND GREGORY G. FREUND

- I. Introduction 406
- II. Proinflammatory Cytokines in Type 2 Diabetes 408
- III. IL-18 and Diabetes 418
- IV. Anti-inflammatory Cytokines in Diabetes 418
- V. Leptin 421
- VI. Conclusions 422
- References 423

# 18

## RELEASE OF INTERLEUKINS AND OTHER INFLAMMATORY CYTOKINES BY HUMAN ADIPOSE TISSUE IS ENHANCED IN OBESITY AND PRIMARILY DUE TO THE NONFAT CELLS

JOHN N. FAIN

- I. Introduction: Most Release of Adipokines/Cytokines by Adipose Tissue Is Due to Nonfat Cells 446
- II. Comparison of Rodent Versus Human Adipose Tissue 447
- III. Interleukin Release by Adipose Tissue 448
- IV. Effect of Obesity on Circulating Cytokines and Release by Adipose Tissue 453
- V. Visceral Versus Subcutaneous Adipose Tissue as a Source of Adipokines/Cytokines 454
- VI. Formation of Adipokines/Cytokines by Adipose Tissue *In Vitro* as Compared to Connective Tissue, the Nonfat Cells in Adipose Tissue, and Adipocytes 455
- VIII. Pathways for Upregulation of Interleukin Release by Human Adipose Tissue 467
- References 469

# 19

## ROLE OF INTERLEUKIN-13 IN CANCER, PULMONARY FIBROSIS, AND OTHER T<sub>H</sub>2-TYPE DISEASES

BHARAT H. JOSHI, CORY HOGABOAM, PAMELA DOVER, SYED R. HUSAIN,  
AND RAJ K. PURI

- I. Introduction 481
- II. IL-13 and Its Receptors 481
- III. IL-13R-Mediated Signal Transduction 483
- IV. Effect of IL-13 on Tumor Cells 484
- V. Targeting IL-13R by IL-13PE Cytotoxin 484
- VI. Significance of IL-13R $\alpha$ 2 Expression 486
- VII. Regulation of IL-13R $\alpha$ 2 Expression 487
- VIII. Clinical Studies with IL-13PE Cytotoxin 487
- IX. IL-13 and Chronic Lung Disease 489
- X. Activity of IL-13PE in Pulmonary Diseases 490
- XA. Asthma and Allergy 490
- XB. *S. Mansoni* Granuloma Formation 492
- XC. Pulmonary Fibrosis 493
- XI. Concluding Remarks 495
- References 496

# 20

## INTERLEUKINS, INFLAMMATION, AND MECHANISMS OF ALZHEIMER'S DISEASE

DAVID WEISMAN, EDWIN HAKIMIAN, AND GILBERT J. HO

- I. Introduction 506
- II. The Inflammatory Response in AD 508
- III. Interleukins as CNS Modulators of Inflammation 510
- IV. Interleukins and the Clinicopathologic Characteristics of AD 510
- V.  $\beta$ -Amyloid, Interleukins, and Inflammatory Signaling in AD 517
- VI. Interleukins: Therapeutic Implications for AD 520
- VII. Conclusions: Future Directions 522
- References 523



# 21

## INTERLEUKIN-2: FROM T CELL GROWTH AND HOMEOSTASIS TO IMMUNE RECONSTITUTION OF HIV PATIENTS

MARKO KRYWORUCHKO AND JACQUES THÈZE

- I. Introduction 532
- II. IL-2 and Its Receptors 532
- III. Physiology and Pathophysiology of IL-2 534
- IV. IL-2R-Dependent Signal Transduction Mechanisms 536
- V. Role of the IL-2 System in HIV Pathogenesis 538
- VI. IL-2 Immunotherapy of HIV Patients 540
- VII. Concluding Remarks 541
- References 542

INDEX 549

# CONTENTS

---

CONTRIBUTORS xv

PREFACE XIX

## 1

### **RXR: FROM PARTNERSHIP TO LEADERSHIP IN METABOLIC REGULATIONS**

BÉATRICE DESVERGNE

- I. Introduction 2
- II. RXRs and Their Many Partners Belong to the Nuclear Receptor Superfamily 3
- III. RXR in Partnership: The Permissive Heterodimers as Metabolic Sensors 7
- IV. The Retinoid-Signaling Pathways: From Partnership to Leadership 15
- V. Conclusions 21
- References 22

## 2

### THE INTERSECTION BETWEEN THE ARYL HYDROCARBON RECEPTOR (AHR)- AND RETINOIC ACID-SIGNALING PATHWAYS

KYLE A. MURPHY, LOREDANA QUADRO, AND LORI A. WHITE

- I. Introduction 34
- II. Retinoid Signaling 38
- III. The AhR/Arnt Pathway 40
- IV. AhR and RA Availability 45
- V. Molecular Interactions Between the RA and AhR Pathways 52
- References 56

## 3

### ROLE OF RETINOIC ACID IN THE DIFFERENTIATION OF EMBRYONAL CARCINOMA AND EMBRYONIC STEM CELLS

DIANNE ROBERT SOPRANO, BRYAN W. TEETS, AND KENNETH J. SOPRANO

- I. Introduction 70
- II. Molecular Mechanism of Action of RA 71
- III. Model Systems to Study Differentiation 73
- IV. Role of RARs 77
- V. RA-Regulated Genes 78
- VI. Role of Specific RA-Regulated Genes 80
- VII. Conclusions 86
- References 87

## 4

### METABOLISM OF RETINOL DURING MAMMALIAN PLACENTAL AND EMBRYONIC DEVELOPMENT

GEOFFROY MARCEAU, DENIS GALLOT, DIDIER LEMERY, AND VINCENT SAPIN

- I. General Aspects of Retinol Transport and Metabolism in Mammalian Species 98
- II. Placental Transport and Metabolism of Retinol During Mammalian Development 101

- III. Embryonic Metabolism of Retinol During  
Mammalian Development 105  
References 109

## 5

### CONVERSION OF $\beta$ -CAROTENE TO RETINAL PIGMENT

HANS K BIESALSKI, GURUNADH R. CHICHILI, JÜRGEN FRANK,  
JOHANNES VON LINTIG, AND DONATUS NOHR

- I. General Aspects of Vitamin A Metabolism 118  
II. Conversion of  $\beta$ -Carotene to Vitamin A 120  
III.  $\beta$ -Carotene as Provitamin A in Retinal Pigment Epithelial Cells 124  
IV. Alternative Routes of Vitamin A Supply 126  
References 128

## 6

### VITAMIN A-STORING CELLS (STELLATE CELLS)

HARUKI SENOO, NAOSUKE KOJIMA, AND MITSURU SATO

- I. Introduction 132  
II. Morphology of HSCs 133  
III. Regulation of Vitamin A Homeostasis by HSCs 134  
IV. HSCs in Arctic Animals 137  
V. Roles of HSCs During Liver Regeneration 141  
VI. Production and Degradation of ECM Components by HSCs 143  
VII. Reversible Regulation of Morphology, Proliferation, and Function of  
the HSCs by 3D Structure of ECM 146  
VIII. Stimulation of Proliferation of HSCs and Tissue Formation of the  
Liver by a Long-Acting Vitamin C Derivative 149  
IX. Extrahepatic Stellate Cells 151  
X. Conclusions 152  
References 153

---

## 7

---

### USE OF MODEL-BASED COMPARTMENTAL ANALYSIS TO STUDY VITAMIN A KINETICS AND METABOLISM

CHRISTOPHER J. CIFELLI, JOANNE BALMER GREEN, AND MICHAEL H. GREEN

- I. Introduction 162
- II. Highlights of Whole-Body Vitamin A Metabolism 163
- III. Early Kinetic Studies of Vitamin A Metabolism 164
- IV. Overview of Compartmental Analysis 166
- V. Use of Model-Based Compartmental Analysis to Study  
Vitamin A Kinetics 169
- VI. Conclusions 191
- References 192

---

## 8

---

### VITAMIN A SUPPLEMENTATION AND RETINOIC ACID TREATMENT IN THE REGULATION OF ANTIBODY RESPONSES *IN VIVO*

A. CATHARINE ROSS

- I. Introduction 199
- II. Rationale for Interest in VA Supplementation and  
Antibody Production 199
- III. VA and the Response to Immunization in Children 202
- IV. Experimental Studies of VA or RA Supplementation and Antibody  
Production *In Vivo* 204
- V. Innate Immune Cells and Factors Regulated by VA and RA That  
May Affect Immunization Outcome 211
- VI. Discussion and Perspectives 215
- References 218

---

**9**

---

**PHYSIOLOGICAL ROLE OF RETINYL PALMITATE  
IN THE SKIN**

PETER P. FU, QINGSU XIA, MARY D. BOUDREAU, PAUL C. HOWARD,  
WILLIAM H. TOLLESON, AND WAYNE G. WAMER

- I. Introduction 224
- II. Structure and Physiological Functions of the Skin 226
- III. Cutaneous Absorption and Deposition of Dietary and Topically Applied Retinol and Retinyl Esters 228
- IV. Mobilization and Metabolism of Retinol and Retinyl Esters in the Skin 241
- V. Effects on Selected Biological Responses of the Skin 243
- VI. Summary 249
- References 249

---

**10**

---

**RETINOIC ACID AND THE HEART**

JING PAN AND KENNETH M. BAKER

- I. Introduction 258
- II. Role of RA in Heart Development and Congenital Heart Defects 259
- III. Postnatal Development Effects of RA in the Heart 268
- IV. Conclusions 273
- References 274

---

**11**

---

**TOCOTRIENOLS IN CARDIOPROTECTION**

SAMARJIT DAS, KALANITHI NESARETNAM, AND DIPAK K. DAS

- I. Introduction 285
- II. A Brief History of Vitamin 286
- III. Tocotrienols and Cardioprotection 292
- IV. Atherosclerosis 293
- V. Tocotrienols in Free Radical Scavenging and Antioxidant Activity 294

- VI. Tocotrienols in Ischemic Heart Disease 295
- VII. Conclusions 296
- References 296

## 12

### CYTODIFFERENTIATION BY RETINOIDS, A NOVEL THERAPEUTIC OPTION IN ONCOLOGY: RATIONAL COMBINATIONS WITH OTHER THERAPEUTIC AGENTS

ENRICO GARATTINI, MAURIZIO GIANNI', AND MINEKO TERAO

- I. Premise and Scope: Differentiation Therapy with Retinoids Is a Significant Goal in the Management of the Neoplastic Diseases 303
- II. The Classical Nuclear RAR Pathway Is Complex and Has Led to the Development of Different Types of Synthetic Retinoids 305
- III. Retinoids Promote Differentiation in Numerous Types of Neoplastic Cells 307
- IV. Retinoids Exert Pleiotropic Effects Interacting with Multiple Intracellular Pathways: An Opportunity for Combination Therapy 313
- V. Retinoid-Based Differentiation Therapy, General Observations, and Conclusion 334
- References 336

## 13

### EFFECTS OF VITAMINS, INCLUDING VITAMIN A, ON HIV/AIDS PATIENTS

SAURABH MEHTA AND WAFIAE FAWZI

- I. Introduction 357
- II. Vitamins and Immune Function 358
- III. Vitamins, HIV Transmission, and Pregnancy Outcomes 360
- IV. Vitamins and HIV Disease Progression in Adults 366
- V. Vitamins, Growth, and Disease Progression in HIV-Infected Children and HIV-Negative Children Born to HIV-Infected Mothers 372
- VI. Comment 374
- VII. Future Research 377
- References 377

---

# 14

---

## VITAMIN A AND EMPHYSEMA

RICHARD C. BAYBUTT AND AGOSTINO MOLteni

- I. Does Vitamin A Protect Against Pulmonary Emphysema? 386
- II. Conclusions 397
- References 398

INDEX 403



# CONTENTS

---

CONTRIBUTORS XVII  
PREFACE XXI

## 1 VITAMIN E

DEBBIE J. MUSTACICH, RICHARD S. BRUNO, AND MARET G. TRABER

- I. Introduction 2
- II. Vitamin E Structures and Function 3
- III. Absorption, Transport, and Distribution to Tissues 4
- IV. The  $\alpha$ -Tocopherol Transfer Protein 6
- V. Regulation of Vitamin E Metabolism and Excretion 8
- VI. Implications for Humans Supplementing with Vitamin E 14
- VII. Conclusion 16
- References 16

## 2

### STRUCTURE AND FUNCTION OF $\alpha$ -TOCOPHEROL TRANSFER PROTEIN: IMPLICATIONS FOR VITAMIN E METABOLISM AND AVED

K. CHRISTOPHER MIN

- I. Introduction 24
- II. Structure of  $\alpha$ -TTP 29
- III. Mutations Associated with AVED 34
- IV. Summary 39
- References 40

## 3

### THE $\alpha$ -TOCOPHEROL TRANSFER PROTEIN

D. MANOR AND S. MORLEY

- I. Introduction 46
- II. Identification of TTP 47
- III. TTP and Vitamin E Status: Ataxia with Vitamin E Deficiency 48
- IV. TTP and Vitamin E Status: TTP<sup>-/-</sup> Mice 51
- V. Biochemical Activities of TTP 51
- VI. Physiological Activities of TTP 53
- VII. Three-Dimensional Structure of TTP 56
- VIII. Selective Retention of RRR- $\alpha$ -TOH and the Evolutionary Origins of TTP 58
- IX. Epilogue 60
- References 60

## 4

### MOLECULAR ASSOCIATIONS OF VITAMIN E

PETER J. QUINN

- I. Introduction 68
- II. Physical Properties of Vitamin E 70
- III. Interaction of Vitamin E with Lipids in Monolayers 70
- IV. Interaction of Vitamin E with Phospholipid Bilayer Membranes 73

- V. Distribution and Orientation of Vitamin E in Phospholipid Membranes 74
- VI. Motion of Vitamin E in Lipid Assemblies 76
- VII. Effect of Vitamin E on Phospholipid Phase Behavior 77
- VIII. Effect of Vitamin E on the Structure of Phospholipid Model Membranes 79
- IX. Phase Separation of Vitamin E in Phospholipid Mixtures 85
  - X. Effect of Vitamin E on Membrane Permeability 88
- XI. Effect of Vitamin E on Membrane Stability 89
- XII. Domains Enriched in Vitamin E in Membranes 91
- XIII. Effect of Vitamin E on Membrane Protein Function 92
- XIV. Conclusions 93
  - References 93

## 5

### **STUDIES IN VITAMIN E: BIOCHEMISTRY AND MOLECULAR BIOLOGY OF TOCOPHEROL QUINONES**

DAVID G. CORNWELL AND JIYAN MA

- I. Introduction 100
- II. Redox Cycling and Arylating Properties of Tocopherol Quinones 103
- III. Identification and Analysis of Tocopherols, Quinones, and Adducts 108
- IV. Arylating Tocopherol Quinones and the Unfolded Protein Response 111
  - V. Tocopherol Quinones and Mutagenesis 112
- VI. Specificity of Phenolic Antioxidant Precursors in Tocopherol Biology 113
- VII. Natural Abundance of Tocopherols and Its Effects on Biology 118
  - References 122

## 6

---

### VITAMIN E AND NF- $\kappa$ B ACTIVATION: A REVIEW

HOWARD P. GLAUERT

- I. Introduction 136
- II. Nuclear Factor- $\kappa$ B 137
- III. In *Vitro* Studies 138
- IV. In *Vivo* Studies 142
- V. Mechanisms by Which Vitamin E May Inhibit  
NF- $\kappa$ B Activation 143
- VI. Is the Inhibition of NF- $\kappa$ B Activation Necessary for Some of the  
Activities of Vitamin E? 145
- VII. Summary 145
- References 145

## 7

---

### SYNTHESIS OF VITAMIN E

THOMAS NETSCHER

- I. Introduction 156
- II. Synthesis of (all-*rac*)- $\alpha$ -Tocopherol 156
- III. Preparation of Optically Active Tocopherols 165
- IV. Synthesis of Tocotrienols 188
- References 194

## 8

---

### TOCOTRIENOLS: THE EMERGING FACE OF NATURAL VITAMIN E

CHANDAN K. SEN, SAVITA KHANNA, CAMERON RINK, AND SASHWATI ROY

- I. Historical Developments and the Vitamin E Family 204
- II. Biosynthesis of Tocopherols and Tocotrienols 206
- III. Changing Trends in Vitamin E Research 208
- IV. Unique Biological Functions of Tocotrienols **210**
- V. Natural Sources of Tocotrienols 212
- VI. Bioavailability of Oral Tocotrienols 213
- VII. Biological Functions 217
- VIII. Conclusion 247
- References 248

---

**9****VITAMIN E BIOTRANSFORMATION IN HUMANS**

FRANCESCO GALLI, M. CRISTINA POLIDORI, WILHELM STAHL,  
PATRIZIA MECOCCI, AND FRANK J. KELLY

- I. Introduction 264
- II. The Fate of Vitamin E from Ingestion to Excretion 264
- III. Biotransformation and Metabolism of Vitamin E as Bioactivation Processes 266
- References 277

---

**10** **$\alpha$ -TOCOPHEROL STEREOISOMERS**

SØREN KROGH JENSEN AND CHARLOTTE LAURIDSEN

- I. Introduction 283
- II. Sources of Tocopherol, Nomenclature, and Bioactivity 284
- III. Analytical Methods for Separation of  $\alpha$ -Tocopherol Stereoisomers 288
- IV. Bioavailability and Secretion into Milk 293
- V. n-Tocopherol-Binding Protein ( $\alpha$ -TTP) 303
- VI. Conclusions 305
- References 305

---

**11****ADDITION PRODUCTS OF  $\alpha$ -TOCOPHEROL WITH LIPID-DERIVED FREE RADICALS**

RYO YAMAUCHI

- I. Introduction 310
- II. Addition Products of  $\alpha$ -Tocopherol with Methyl Linoleate-Derived Free Radicals 311
- III. Addition Products of n-Tocopherol with PC-Peroxy Radicals in Liposomes 314
- IV. Addition Products of n-Tocopherol with CE-Peroxy Radicals 317
- V. Detection of the Addition Products of n-Tocopherol with Lipid-Peroxy Radicals in Biological Samples 318
- References 324

# 12

## VITAMIN E AND APOPTOSIS

PAUL W. SYLVESTER

- I. Introduction 330
- II. Vitamin E and Vitamin E Derivatives 331
- III. Vitamin E Antioxidant Potency 334
- IV. Vitamin E as an Anticancer Agent 336
- V. Apoptosis 339
- VI. Vitamin E Suppression of Apoptosis 341
- VII. Vitamin E-Induced Apoptosis 342
- VIII. Conclusion 348
- References 348

# 13

## VITAMIN E DURING PRE- AND POSTNATAL PERIODS

CATHY DEBIER

- I. Introduction 358
- II. Prenatal Transfer of Vitamin E 359
- III. Postnatal Transfer of Vitamin E 364
- IV. Vitamin E in Critical Situations 366
- References 368

# 14

## $\alpha$ -TOCOPHEROL: A MULTIFACETED MOLECULE IN PLANTS

SERGI MUNNÉ-BOSCH

- I. Introduction 376
- II. Occurrence and Antioxidant Function of  $\alpha$ -Tocopherol in Plants 377
- III. Photoprotective Function of  $\alpha$ -Tocopherol in Plants 380
- IV.  $\alpha$ -Tocopherol and the Stability of Photosynthetic Membranes 383
- V. Role of  $\alpha$ -Tocopherol in Cellular Signaling 383
- VI. Have the Functions of Tocopherols Been Evolutionary Conserved? 385

- VII. Future Perspectives 387  
References 387

## 15

### VITAMIN E AND MAST CELLS

JEAN-MARC ZINGG

- I. Introduction 394  
II. Cellular Effects of Vitamin E in Mast Cells 397  
III. Preventive Effects of Vitamin E on Diseases with Mast Cell Involvement 406  
IV. Summary 409  
References 410

## 16

### TOCOTRIENOLS IN CARDIOPROTECTION

SAMARJIT DAS, KALANITHI NESARETNAM, AND DIPAK K. DAS

- I. Introduction 420  
II. A Brief History of Vitamin 420  
III. Vitamin E, Now and Then 421  
IV. Tocotrienols versus Tocopherols 423  
V. Sources of Tocotrienols 426  
VI. Tocotrienols in Free Radical Scavenging and Antioxidant Activity 426  
VII. Tocotrienols and Cardioprotection 427  
VIII. Atherosclerosis 427  
IX. Tocotrienols in Ischemic Heart Disease 429  
X. Summary and Conclusion 430  
References 430

## 17

### VITAMIN E AND CANCER

KIMBERLY KLINE, KARLA A. LAWSON, WEIPING YU, AND BOB G. SANDERS

- I. Basic Information About Vitamin E 436  
II. Intervention Trials 441

- III. Preclinical Studies 443
- IV. Anticancer Mechanisms of Action of Vitamin E-Based Compounds 446
- V. What About Vitamin E Supplementation and Cancer Survivorship? 453
- VI. Conclusions 453
- References 454

## 18

### VITAMIN E ANALOGUES AND IMMUNE RESPONSE IN CANCER TREATMENT

MARCO TOMASETTI AND JIRI NEUZIL

- I. Introduction 464
- II. Vitamin E Analogues as Anticancer Agents 466
- III. Vitamin E Analogues as Adjuvants in Cancer Chemotherapy 473
- IV. Immunological Inducers of Apoptosis: Mechanisms and Clinical Application in Cancer 473
- V. Targeting Immune Surveillance 481
- VI. Conclusions 483
- References 483

## 19

### THE ROLES OF $\alpha$ -VITAMIN E AND ITS ANALOGUES IN PROSTATE CANCER

JING NI AND SHUYUAN YEH

- I. Introduction 494
- 11. Family Members, Source, and Proper Supplemental Dose of Vitamin E 495
- III. General Physiological Function of Vitamin E 496
- IV. Vitamin E Absorption and Transport 497
- V.  $\alpha$ -Vitamin E-Binding Proteins 498
- VI. Vitamin E and Diseases 501
- VII.  $\alpha$ -Vitamin E Function in Prostate Cancer: Clinical Studies 501
- VIII.  $\alpha$ -Vitamin E Function in Prostate Cancer: Animal Studies 506
- IX.  $\alpha$ -Vitamin E in Prostate Cancer: Molecular Mechanism Studies in Cancer Cells 507



- X. Summary and Perspectives 510  
References 512

## **20**

### **VITAMIN E: INFLAMMATION AND ATHEROSCLEROSIS**

U. SINGH AND S. DEVARAJ

- I. Introduction 520  
II. Inflammation and Atherosclerosis 521  
III. Vitamin E 522  
IV. Animal Studies 523  
V. Intervention Studies 530  
VI. Other Forms of Vitamin E 531  
VII. Tocotrienols 536  
VIII. Hypocholesterolemic Effect 537  
IX. Antiinflammatory Effects 541  
X. Antioxidant Effect 541  
XI. Mechanism of Action and Future Direction 542  
XII. Conclusion 542  
References 543

## **21**

### **VITAMIN E IN CHRONIC LIVER DISEASES AND LIVER FIBROSIS**

ANTONIO DI SARIO, CINZIA CANDELARESI, ALESSIA OMENETTI,  
AND ANTONIO BENEDETTI

- I. Fibrosis in Chronic Liver Diseases 552  
II. Oxidative Stress, Chronic Liver Disease, and Liver Fibrosis 554  
References 567

INDEX 575

# CONTENTS

<b>Contributors</b>	<i>xiii</i>
<b>Preface</b>	<i>xvii</i>
<b>■ The Structure of Ghrelin</b>	<b>1</b>
Andreas Kukol	
I. Introduction	2
II. Background	2
III. Results of Structural Studies	5
IV. Discussion	9
V. Conclusions	11
References	11
<b>2. Biochemistry of Ghrelin Precursor Peptides</b>	<b>13</b>
Chris J. Pemberton and A. Mark Richards	
I. Introduction	14
II. Ghrelin Gene Precursors	15
III. Posttranslational Products of Proghrelin	17
IV. Distribution of Proghrelin Peptides	22
V. Proghrelin Peptides in Lower Vertebrates	24
VI. Summary	25
References	25
<b>3. Structure of Mammalian and Nonmammalian Ghrelins</b>	<b>31</b>
Masayasu Kojima, Takanori Ida, and Takahiro Sato	
I. Introduction	32
II. Mammalian Ghrelin	33
III. Nonmammalian Ghrelin	36
IV. Ghrelin and Motilin Family	40
V. Activity Change by Fatty Acid Chain Length of Ghrelin	41
VI. Putative Ghrelin Acyl-Modifying Enzyme	41
VII. Conclusion	43
References	43

4. The Growth Hormone Secretagogue Receptor	<b>47</b>
Conrad Russell Young <b>Cruz</b> and Roy G. Smith	
I. Introduction: A Case of Reverse Pharmacology	48
II. Genetics and Molecular Biology	49
III. Regulation of Gene Expression	55
IV. Signal Transduction	58
V. GHSR $\alpha$ : Tissue Distribution and Functions in Different Organ Systems	62
VI. Other Ligands	74
VII. Evidence for Other Receptors	77
VIII. Future Directions	78
References	79
5. Basic Aspects of Ghrelin Action	<b>89</b>
Yolanda Pazos, Felipe F. Casanueva, and <b>Jesus P. Camiia</b>	
I. Introduction	90
II. Structure of <b>GHSR1<math>\alpha</math></b> : A <b>G-Protein-Coupled</b> Receptor	91
III. How to Define the Role of the System Ghrelin/ <b>GHSR1<math>\alpha</math></b> ?	96
IV. Are There Alternative Ligands for the <b>GHSR1<math>\alpha</math></b> ?	97
V. Endocytosis of <b>GHSR1<math>\alpha</math></b>	98
VI. Homo- or Heteromeric Complexes for <b>GHSR1<math>\alpha</math></b>	99
VII. <b>GHSR1<math>\alpha</math></b> : G-Protein-Signaling Pathways	101
VIII. A Brief Commentary: "New" Receptors for Ghrelin and Desacyl Ghrelin	107
IX. Concluding Remarks	108
References	109
6. Appetite and Metabolic Effects of Ghrelin and Cannabinoids: <b>Involvement</b> of AMP-Activated Protein Kinase	121
Hinke van <b>Thuijl</b> , <b>Blerina Kola</b> , and Marta Korbonits	
I. Introduction	122
II. Ghrelin	122
III. Cannabinoids	127
IV. Adenosine Monophosphate-Activated Protein Kinase	131
V. The Effects of Ghrelin and Cannabinoids on AMPK	135
References	138
7. Ghrelin and Feedback Systems	<b>149</b>
Katsunori Nonogaki	
I. Introduction	150
II. Regulation of Ghrelin Secretion	151

III. Afferent Pathways of Ghrelin from the Stomach to the Hypothalamus	158
IV. Hyperphagia, Obesity, and Des-acyl Ghrelin	159
V. Hypothalamic Gene Expression and Plasma Des-acyl Ghrelin	161
VI. Conclusion	161
References	162
<b>8. Ghrelin Gene-Related Peptides Modulate Rat White Adiposity</b>	<b>171</b>
Andrés Giovambattista, Rolf C. Gaillard, and Eduardo Spinedi	
I. Introduction	172
II. Effects of Ghrelin on Rat Retroperitoneal Adipocyte Endocrine Functions	176
III. Desacyl Ghrelin as a Potential Physiological Modulator of Adiposity	183
IV. Discussion and Remarks	193
References	199
<b>9. Cardiac, Skeletal, and Smooth Muscle Regulation by Ghrelin</b>	<b>207</b>
Adelino F. Leite-Moreira, Amândio Rocha-Sousa, and Tiago Henriques-Coelho	
I. Introduction	208
II. Structure and Distribution of Ghrelin	210
III. Contractile Effects of Ghrelin	217
References	230
<b>10. Ghrelin and Bone</b>	<b>239</b>
Martijn van der Velde, Patric Delhanty, Bram van der Eerden, Aart Jan van der Lely, and Johannes van Leeuwen	
I. Bone Balance: Resorption and Formation	239
II. Interplay Between the Gastrointestinal System and Bone: The Effect of Gastrectomy/Fundectomy on Bone	240
III. Effects of GH and GHS on Bone Metabolism	242
IV. Correlation Between Ghrelin and Bone Parameters in Clinical Studies	244
V. Effects of Ghrelin on Osteoblastic Cells In Vitro	245
VI. Conclusions	249
References	249
<b>11. Ghrelin in Pregnancy and Lactation</b>	<b>259</b>
Iens Fuglsang	
I. Introduction	260
II. GHSRs in Pregnancy	260

III. Ghrelin in the Fallopian Tubes, Uterus, and Placenta	262
IV. Ghrelin Secretion in Pregnancy	262
V. Placenta as a Source of Ghrelin?	265
VI. Physiological Actions of Ghrelin in Pregnancy	266
VII. Lactation	273
VIII. Fetal Ghrelin	274
IX. Future Directions for Research	276
X. Summary	276
References	277
<b>12. Ghrelin and Reproduction: Ghrelin as Novel Regulator of the Gonadotropic Axis</b>	<b>285</b>
Manuel Tena-Sempere	
I. Introduction: Ghrelin is a Multifunctional Regulator with Key Roles in Energy Balance	286
II. Neuroendocrine Control of Reproduction: The Gonadotropic Axis	287
III. Reproduction and the Energy Status are Functionally Linked	288
IV. Ghrelin as Putative Regulator of the Gonadotropic Axis	289
V. Role of Ghrelin in the Control of Gonadotropin Secretion	289
VI. Putative Roles of Ghrelin in Puberty Onset	291
VII. Molecular Diversity of Ghrelin: Reproductive Effects of UAG and Obestatin	292
VIII. Expression and Direct Actions of Ghrelin in the Gonads	293
IX. Futures Perspectives and Conclusions	295
References	298
<b>13. Ghrelin and Prostate Cancer</b>	<b>301</b>
Fabio Lanfranco, Matteo Baldi, Paola Cassoni, Martino Bosco, Corrado Ghé, and Giampiero Muccioli	
I. Prostate Cancer	302
II. Influences of Hormones on Prostate Cancer Progression	303
III. The Peptide Hormone Ghrelin and Prostate Cancer	307
IV. Conclusions	315
References	316
<b>14. Novel Connections Between the Neuroendocrine and Immune Systems: The Ghrelin Immunoregulatory Network</b>	<b>325</b>
Dennis D. Taub	
I. Neuroendocrine–Immune Interactions	326
II. The Growth Hormone Secretagogue Receptor	327

---

III. Ghrelin: Hormone or Cytokine?	329
IV. Conclusions	341
References	342
<b><i>Index</i></b>	<b>347</b>

# CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xix</i>
<b>1. Determinants of Vitamin K Status in Humans</b>	<b>1</b>
Sarah L. Booth and Ala Ai Rajabi	
I. Introduction	2
II. Assessment of Vitamin K Status	2
III. Nongenetic Determinants	5
IV. Genetic Determinants	14
V. Conclusions and Future Directions	16
Acknowledgments	17
References	17
<b>2. VKORC<sub>1</sub> and the Vitamin K Cycle</b>	<b>23</b>
Andrea A. Garcia and Pieter H. Reitsma	
I. Vitamin K Cycle: Limiting Step of Carboxylation	24
II. VKOR: Is It a Complex?	27
III. VKORC <sub>1</sub> in Clinical Practice	29
IV. Conclusion	31
Acknowledgment	31
References	32
<b>3. The Vitamin K Cycle</b>	<b>35</b>
Johannes Oldenburg, Milka Marinova, Clemens Müller-Reible, and Matthias Watzka	
I. Introduction	36
II. Vitamin K Biosynthesis	37
III. Vitamin K Cycle	39
IV. Physiological Role of Vitamin K Dependent Proteins	44
V. Clinical Phenotypes Related to the Vitamin K Pathway in Man	47
VI. Conclusions and Perspectives	53
Acknowledgments	54
References	54

---

<b>4. Structure, Function, and Mechanism of Cytosolic Quinone Reductases</b>	<b>63</b>
Mario A. Bianchet, Sabri Bora Erdemli, and L. Mario Amzel	
I. Introduction	64
II. Quinone Reductase Type 1	65
III. Quinone Reductase Type 2	77
IV. Disclaimer	79
References	79
<b>5. Quinone Oxidoreductases and Vitamin K Metabolism</b>	<b>85</b>
Xing Gong, Ramana Gutala, and Anil K. Jaiswal	
I. Vitamin K and Vitamin K Cycle	86
II. Quinone Oxidoreductases	87
III. Quinone Oxidoreductases and Reduction of Vitamin K to Hydroquinone	91
IV. Quinone Oxidoreductases and Metabolic Detoxification or Activation of Vitamin K	93
V. Quinone Oxidoreductases and Anticancer Effects of Vitamin K	95
VI. Future Perspectives	96
Acknowledgments	96
References	96
<b>6. Structure and Function of Vitamin K Epoxide Reductase</b>	<b>103</b>
Jian-Ke Tie and Darrel W. Stafford	
I. Introduction	104
II. Purification of VKOR	106
III. Mechanism of Vitamin K Epoxide Reduction Catalyzed by VKOR	110
IV. Identification of the Active Site of VKOR	115
V. Warfarin inhibition of VKOR	117
VI. Membrane Topology of VKOR	122
VII. Conclusion	124
References	125
<b>7. Vitamin K-Dependent Carboxylation</b>	<b>131</b>
Kathleen L. Berkner	
I. Vitamin K-Dependent Protein Function	132
II. Vitamin K Forms	134
III. Mechanism of Carboxylation	135
IV. Functional Regions of the Carboxylase	138



V. Vitamin K Reduction Is Required for Carboxylation in Tissue	142
VI. Carboxylation Interfaces with Secretion	144
VII. The Capacity of Vitamin K-Dependent Protein Carboxylation Is Limited in Cultured Cells	146
VIII. Summary	148
References	149
<b>8. Vitamin K-Dependent <math>\gamma</math>-Glutamylcarboxylation: An Ancient Posttranslational Modification</b>	<b>157</b>
Pradip K. Bandyopadhyay	
I. Introduction	158
II. Reviews	159
III. $\gamma$ -Carboxylation Reaction	159
IV. Vitamin K Cycle	161
V. Mechanism of $\gamma$ -Carboxylation	162
VI. Proposed Topology of $\gamma$ -Glutamyl Carboxylase	162
VII. Substrate Recognition (Propeptide)	163
VIII. Structure-Function Relationship	164
IX. Expression of GGCX During Development	166
X. Gla-Containing Proteins and $\gamma$ -Carboxylase in Urochordate	166
XI. <i>Drosophila</i> $\gamma$ -Glutamyl Carboxylase	167
XII. $\gamma$ -Carboxylated Peptides in <i>Conus</i>	167
XIII. <i>Conus</i> $\gamma$ -Glutamyl Carboxylase	174
XIV. Future Prospects	175
Acknowledgments	177
References	177
<b>9. Vitamin K-Dependent Actions of Gas6</b>	<b>185</b>
Lola Bellido-Martín and Pablo Garcia de Frutos	
I. Introduction	186
II. Gas6 Structure	186
III. Cellular Effects of Gas6	187
IV. Interaction with TAM Receptor Molecules and Signal Transduction in the <b>Gas6/TAM Ligand/Receptor</b> System	191
V. Role of the <b>Gas6/TAM</b> System in Vascular Biology	194
VI. Gas6 in Innate Immunity: A Modulator of the Inflammatory Response	195
VII. Further Functions of <b>Gas6/TAM</b> Receptors in Cellular Homeostasis	197
VIII. Overlapping Functions of Gas6 and Protein S	197
IX. The Implications of Vitamin K in Gas6 Function	199
Acknowledgment	200
References	200

<b>10. Vitamin K<sub>2</sub>-Mediated Apoptosis in Cancer Cells: Role of Mitochondria1 Transmembrane Potential</b>	<b>211</b>
Toshiko Shibayama-Imazu, Toshihiro Aiuchi, and Kazuyasu Nakaya	
I. Introduction	212
II. Growth-Inhibitory Effect of Vitamin K <sub>2</sub>	213
III. Induction of Differentiation of Leukemia Cells by Vitamin K <sub>2</sub>	213
IV. Induction of Apoptosis by Vitamin K <sub>2</sub> in Human Cancer Cells	214
V. Association with Reduced Mitochondrial Membrane Potential ( $\Delta\Psi_m$ )	217
VI. Conclusion	221
References	222
<b>11. VKORC1: A Warfarin-Sensitive Enzyme in Vitamin K Metabolism and Biosynthesis of Vitamin K-Dependent Blood Coagulation Factors</b>	<b>227</b>
Reidar Wallin, Nadeem Wajih, and Susan M. Hutson	
I. Introduction	228
II. The Vitamin K-Dependent $\gamma$ -Carboxylation System	231
III. Genetics of Warfarin Resistance	241
IV. Future Perspectives	242
References	242
<b>12. Warfarin Therapy: Influence of Pharmacogenetic and Environmental Factors on the Anticoagulant Response to Warfarin</b>	<b>247</b>
Virginie Siguret, Eric Pautas, and Isabelle Guoin-Thibault	
I. Introduction	248
II. Vitamin K and Vitamin K Antagonists and Blood Coagulation	249
III. Pharmacology of Warfarin	251
IV. Influence of Environmental Factors on the Anticoagulant Response to Warfarin	253
V. Influence of Pharmacogenetics on the Anticoagulant Response to Warfarin	257
VI. Conclusion	261
References	261
<b>13. Vitamin K and Thrombosis</b>	<b>265</b>
Geno I. Merli and James Fink	
I. Introduction	266
II. Pharmacology of Vitamin K	266
III. Therapeutic Uses of Vitamin K	269
IV. Patients with Major Hemorrhage	271
V. Patients Without Bleeding but Prolonged INR	271
VI. New Physiologic Functions of Vitamin K	274

<b>VII. Warfarin Effects on Vitamin K</b>	<b>275</b>
<b>VIII. Summary</b>	<b>276</b>
References	276
<b>14. Congenital Bleeding Disorders of the Vitamin K-Dependent Clotting Factors</b>	<b>281</b>
A. Girolami, R. Scandellari, M. Scapin, and S. Vettore	
I. Introduction	283
II. Congenital Prothrombin (Factor II) Deficiency	285
III. Congenital Factor VII Deficiency	303
IV. Congenital Factor IX Deficiency (Hemophilia B)	318
V. Congenital Factor X Deficiency	329
VI. Combined Congenital Deficiency of FII, FVII, FIX, FX	347
VII. Deficiency of Protein Z	354
VIII. Conclusions	355
References	357
<b>15. Role of Growth Arrest-Specific Gene 6 in Diabetic Nephropathy</b>	<b>375</b>
Hidenori Arai, Kojiro Nagai, and Toshio Doi	
I. Introduction	376
II. Role of Gas6 in STZ-Induced Diabetic Rats	377
III. <i>In Vitro</i> Effect of Gas6 in Mesangial Cells	381
IV. Role of the Akt Pathway in Diabetic Nephropathy	382
V. High Glucose Induces Mesangial Hypertrophy Via <i>Gas6/Axl In Vitro</i>	386
VI. Study Using <i>Gas6</i> -Knockout Mice	388
VII. Conclusions	389
Acknowledgments	391
References	391
<b>16. Vitamin K and Bone Health In Adult Humans</b>	<b>393</b>
Susanne Bügel	
I. Introduction	394
II. Vitamin K Intake and Bone Health	397
III. Reasons for the Inconsistent Results	405
IV. Vitamin K Recommendations	408
V. Anticoagulation Treatment and Risk of Osteoporosis	409
VI. Interactions Between Vitamin K and Vitamin D	410
VII. Discussion and Conclusion	411
References	411

---

<b>17. Diagnosis of Osteoporosis with Vitamin K as a New Biochemical Marker</b>	<b>417</b>
C. Heiss, L. M. Hoesel, U. Wehr, S. Wenisch, I. Drosse, V. Alt, C. Meyer, U. Horas, M. Schieker, and R. Schnettler	
I. Introduction	418
II. The Important Role of Vitamin K in Bone Metabolism	421
III. Biochemical Markers as Indices of Bone Turnover	428
Acknowledgments	429
References	429
<b>18. Hepatocellular Carcinoma and Vitamin K</b>	<b>435</b>
Toshihiko Mizuta and Iwata Ozaki	
I. Introduction	435
II. Antitumor Effects of VK	436
III. Mechanism of Growth Inhibition of HCC Cells by VK <sub>2</sub>	437
IV. Analysis of Tumor Recurrence Suppression Following Liver Cancer Treatment	439
V. Future Tasks	440
References	440
<i>Index</i>	<b>443</b>

## CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xvii</i>
<b>1. Folate-Mediated One-Carbon Metabolism</b>	<b>1</b>
Jennifer T. Fox and Patrick J. Stover	
I. Overview	2
II. Introduction to Cytoplasmic One-Carbon Metabolism	4
III. Introduction to Mitochondrial One-Carbon Metabolism	24
IV. Nuclear Folate-Mediated One-Carbon Metabolism	28
Acknowledgments	29
References	29
<b>2. Mathematical Models of Folate-Mediated One-Carbon Metabolism</b>	<b>45</b>
H. F. Nijhout, M. C. Reed, and C. M. Ulrich	
I. Introduction	46
II. Structure and Function of the Cycles	49
III. Why Mathematical Modeling?	51
IV. Model Development	61
V. Blood Versus Intracellular Metabolite Concentrations	66
VI. Modeling Gene–Gene and Gene–Environment Interactions	67
VII. Modeling and Simulation have Revealed Novel Homeostatic Mechanisms	70
VIII. Steady States and Fluctuations	75
IX. Conclusions	77
Acknowledgments	78
References	78
<b>3. Folate Deprivation, the Methionine Cycle, and Alzheimer's Disease</b>	<b>83</b>
Flaubert Tchanchou and Thomas B. Shea	
I. Introduction	84
II. Folate Metabolism, the Transmethylation Pathway, and AD	85
III. The Transsulfuration Pathway—Homocysteine Elimination and Glutathione Metabolism	90
References	94
	vii

III. Biological Systems Impacted by B <sub>12</sub> and Folate-Dependent Methyltransferases	297
IV. Structure and Function of B <sub>12</sub> in Methyltransferases	301
V. Activation of the Methyl Group Donors	307
VI. Activation of the Methyl Group Acceptors: Zn Thiolates and NiFeS Clusters	314
Acknowledgments	317
References	317
<b>11. Methyltetrahydrofolate in Folate-Binding Protein Glycine N-Methyltransferase</b>	<b>325</b>
Zigmund Luka	
I. Introduction	326
II. 5-Methyltetrahydrofolate in Folate Metabolism	326
III. Folate-Binding Enzymes	330
IV. Glycine N-Methyltransferase	331
V. GNMT as Methyltetrahydrofolate-Binding Protein	335
VI. Conclusions	340
Acknowledgments	341
References	341
<b>12. Mechanism-Based Inhibitors of Folylpoly-<math>\gamma</math>-Glutamate Synthetase and <math>\gamma</math>-Glutamyl Hydrolase: Control of Folylpoly-<math>\gamma</math>-Glutamate Homeostasis as a Drug Target</b>	<b>347</b>
James K. Coward and John J. McGuire	
I. Introduction	348
II. Folylpoly- $\gamma$ -Glutamate Homeostasis as a Drug Target	350
III. Design of Fluoroglutamate-Containing Folates and Antifolates as FPGS or GH Alternate Substrates and/or Inhibitors	354
IV. Synthesis of Fluorine-Containing Folates and Antifolates from the Corresponding Fluoroglutamates and Related Fluoroamino Acids	356
V. Design of Phosphorus-Containing Pseudopeptides as FPGS Inhibitors	361
VI. Design of Epoxide-Containing Peptidomimetics as GH Inhibitors	366
VII. Conclusions	366
Acknowledgment	367
References	367
<b>13. Methylene tetrahydrofolate Reductase, Common Polymorphisms, and Relation to Disease</b>	<b>375</b>
Philip Thomas and Michael Fenech	
I. Introduction	376
II. Conclusions	386
References	386

<b>14. Mitochondrial Methylenetetrahydrofolate Dehydrogenase, Methenyltetrahydrofolate Cyclohydrolase, and Formyltetrahydrofolate Synthetases</b>	<b>393</b>
Karen E. Christensen and Robert E. MacKenzie	
I. Introduction	394
II. Yeast Mitochondria Contain a Trifunctional Dehydrogenase–Cyclohydrolase–Synthetase	395
III. Mammalian Mitochondrial Methylenetetrahydrofolate Dehydrogenase	395
IV. Mitochondrial Formyltetrahydrofolate Synthetase	403
V. Conclusion	405
References	408
<b>15. The Structure and Mechanism of 6-Hydroxymethyl-7, 8-Dihydropterin Pyrophosphokinase</b>	<b>411</b>
Jeremy P. Derrick	
I. Introduction	412
II. Structural and Mechanistic Studies on EcoHPPK	413
III. Structures of HPPKs from Other Organisms	421
IV. Kinetics	424
V. Relationship of HPPK to Other Pyrophosphoryl Transfer Enzymes	426
VI. Concluding Remarks	429
References	430
<i>Index</i>	435

# CONTENTS

<i>Contributors</i>	xv
<i>Preface</i>	xxi
<b>1. The Human Insulin Superfamily of Polypeptide Hormones</b>	<b>1</b>
Fazel Shabanpoor, Frances Separovic, and John D. Wade	
I. Introduction	2
II. Relaxin Peptide Hormone Subfamily	10
III. Concluding Remarks	22
Acknowledgments	22
References	22
<b>2. The Structure and Function of Insulin: Decoding the TR Transition</b>	<b>33</b>
Michael A. Weiss	
I. Introduction	34
II. Structure–Activity Relationships	38
III. Implications for the Genetics of Diabetes Mellitus	44
IV. Concluding Remarks	45
Acknowledgments	46
References	46
<b>3. Molecular Mechanisms of Differential Intracellular Signaling From the Insulin Receptor</b>	<b>51</b>
Maja Jensen and Pierre De Meyts	
I. Overview	52
II. Insulin and the IR	53
III. Modulation of IR Activity	57
IV. Differential Activation of the IR	63
V. Conclusions/Final Words	67
References	68



<b>4. c-Abl and Insulin Receptor Signalling</b>	<b>77</b>
Marco Genua, Giuseppe Pandini, Maria Francesca Cassarino, Rosa Linda Messina, and Francesco Frasca	
I. Introduction	78
II. Insulin and IGF-IRs	79
III. Metabolic Versus Mitogenic Effect of IR	83
IV. c-Abl Tyrosine Kinase	87
V. c-Abl and IR Signalling	93
VI. Concluding Remarks	98
Acknowledgments	99
References	99
<b>5. CXCL14 and Insulin Action</b>	<b>107</b>
Takahiko Hara and Yuki Nakayama	
I. Introduction	108
II. Basic Properties of CXCL14	109
III. Biological Activities of CXCL14	113
IV. Novel Functions of CXCL14 Revealed by Knockout Mice	115
V. Signal Cross-Talk Between CXCL14 and Insulin	119
VI. CXCL14 as a Metabolic Regulator	119
VII. Conclusions	121
References	121
<b>6. Crosstalk Between Growth Hormone and Insulin Signaling</b>	<b>125</b>
Jie Xu and Joseph L. Messina	
I. Introduction	126
II. GH Signaling	127
III. Insulin Signaling	130
IV. Regulation of GH Signaling by Insulin	131
V. Regulation of Insulin Signaling by Chronic GH	140
VI. Conclusions	142
Acknowledgments	143
References	143
<b>7. Intracellular Retention and Insulin-Stimulated Mobilization of GLUT4 Glucose Transporters</b>	<b>155</b>
Bradley R. Rubin and Jonathan S. Bogan	
I. Introduction	156
II. GLUT4 Storage Vesicles (GSVs)	158
III. Insulin-Regulated Aminopeptidase (IRAP)	162

IV. Stability and Trafficking of GLUT4 and IRAP	164
V. TUG, an Essential Component of a Retention Receptor for GLUT4	166
VI. From What Membranes do GSVs Originate?	174
VII. A General Mechanism for the Regulated Targeting of Membrane Proteins	176
VIII. Conclusions	179
Acknowledgments	179
References	179
<b>8. Compartmentalization and Regulation of Insulin Signaling to GLUT4 by the Cytoskeleton</b>	<b>193</b>
Craig A. Eyster and Ann Louise Olson	
I. Introduction	194
II. Insulin Signaling to GLUT4 Vesicles	195
III. GLUT4 Vesicle Membrane Trafficking	200
IV. GLUT4 Vesicle Fusion	205
V. Conclusions	208
Acknowledgments	208
References	208
<b>9. Nutrient Modulation of Insulin Secretion</b>	<b>217</b>
Nimbe Torres, Lilia Noriega, and Armando R. Tovar	
I. Introduction	218
II. Overview of Insulin Secretion	219
III. Nutrient Regulation of Insulin Secretion	224
References	238
<b>10. How Insulin Regulates Glucose Transport in Adipocytes</b>	<b>245</b>
Joseph M. Muretta and Cynthia Corley Mastick	
I. Introduction	246
II. Historical Perspective	250
III. Current Views and Controversies	265
IV. Conclusions and Future Directions	277
References	278
<b>11. Spatio-Temporal Dynamics of Phosphatidylinositol-3, 4,5-Trisphosphate Signalling</b>	<b>287</b>
Anders Tengholm and Olof Idevall-Hagren	
I. Introduction	288
II. Synthesis and Degradation of PIP <sub>3</sub>	289

III. Real-Time Measurements of PIP <sub>3</sub> in Living Cells	292
IV. Spatio-Temporal Patterns of PIP <sub>3</sub> Signals	295
V. PIP <sub>3</sub> Oscillations and Autocrine Insulin Signalling in $\beta$ -Cells	297
VI. Significance of PIP <sub>3</sub> Oscillations	300
VII. Concluding Remarks	302
Acknowledgments	303
References	303
<b>12. Serine Kinases of Insulin Receptor Substrate Proteins</b>	<b>313</b>
Sigalit Boura-Halfon and Yehiel Zick	
I. Introduction	314
II. Insulin and IGF-1 Signaling	314
III. Regulation of Insulin and IGF-1 Signaling: Role of Ser/Thr Phosphorylation of IRS Proteins	319
IV. The Consequences of Ser Phosphorylation of IRS Proteins	328
V. Ser Phosphorylation of IRS Proteins as an Array Phenomenon	333
VI. Summary	336
References	337
<b>13. Phosphorylation of IRS Proteins: Yin-Yang Regulation of Insulin Signaling</b>	<b>351</b>
Xiao Jian Sun and Feng Liu	
I. Introduction	352
II. Discovery of the IRS Proteins	353
III. Molecular Structure of the IRS Proteins	354
IV. Biological Function of IRS Proteins in Insulin Action	364
V. The Role of IRS Serine Phosphorylation in Mediating the Crosstalk with Other Signaling Pathways	366
VI. Mechanisms Underlying IRS Serine Phosphorylation-Induced Insulin Resistance	369
VII. Conclusion	372
References	373
<b>14. IRS-2 and Its Involvement in Diabetes and Aging</b>	<b>389</b>
Jiandi Zhang and Tian-Qiang Sun	
I. Introduction	390
II. Identification of IRS-2 Protein	391
III. Basic Structure of IRS Family Proteins	392
IV. Involvement of IRS Proteins in Other Signaling Pathways	392
V. IRS-2 Protein is Well Conserved Across Species	393
VI. IRS-2, and Its Regulation in Energy Homeostasis	393

VII. Searching for the Regulatory Factor of IRS-2 Transcription	395
VIII. Phenotype of IRS-2 Null Mice	397
IX. The Role of IRS-2 in Female Reproduction	400
X. The Putative Role of IRS-2 in Aging Process	400
XI. Summary	402
References	403
<b>15. Glucose-Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)</b>	<b>409</b>
Christopher H. S. McIntosh, Scott Widenmaier, and Su-Jin Kim	
I. Introduction	410
II. Glucose-Dependent Insulinotropic Polypeptide (GIP)	412
III. The GIP Gene and Precursor	415
IV. GIP Secretion and Metabolism	417
V. The GIP Receptor	421
VI. Actions of GIP	425
VII. GIP-Activated Signal-Transduction Pathways	432
VIII. Pathophysiology of GIP	439
Acknowledgments	444
References	444
<b>16. Insulin Granule Biogenesis, Trafficking and Exocytosis</b>	<b>473</b>
June Chunqiu Hou, Le Min, and Jeffrey E. Pessin	
I. Introduction	474
II. Section I	476
III. Section II	480
IV. Section III	484
V. Section IV	491
References	494
<b>17. Glucose, Regulator of Survival and Phenotype of Pancreatic Beta Cells</b>	<b>507</b>
Geert A. Martens and Daniel Pipeleers	
I. Scope	508
II. Beta Cell Handling of Glucose: Metabolic Specializations to Ensure Low-Affinity/High Capacity Glucose Sensing	509
III. Glucose as Regulator of the Differentiated Beta Cell Phenotype	512
IV. Glucose Regulation of Beta Cell Number	518
V. Beta Cell Handling of Threatening High and Low Glucose Levels	521
Acknowledgments	530
References	530

<b>18. Matrix Metalloproteinases, T Cell Homing and <math>\beta</math>-Cell Mass in Type 1 Diabetes</b>	<b>541</b>
Alexei Y. Savinov and Alex Y. Strongin	
I. Matrix Metalloproteinases and Their Natural Protein Inhibitors	542
II. T Cell Membrane Type-1 Matrix Metalloproteinase	547
III. Rodent Model of Human Type 1 Diabetes	550
IV. T Cell MT1-MMP and CD44 in T1D	552
Acknowledgment	556
References	556
<b>19. Role of Wnt Signaling in the Development of Type 2 Diabetes</b>	<b>563</b>
Michael Bordonaro	
I. Introduction	564
II. Wnt Signaling	565
III. <i>TCF7L2</i> Variants and Type 2 Diabetes Risk	570
IV. Functional Relationship Between Wnt Signaling and Type 2 Diabetes <i>In Vitro</i>	574
V. Conclusions and Future Directions	575
References	578
<b>20. Retinal Insulin Receptor Signaling In Hyperosmotic Stress</b>	<b>583</b>
Raju V. S. Rajala, Ivana Ivanovic, and Ashok Kumar Dilly	
I. Introduction	584
II. Experimental Procedures	586
III. Results	590
IV. Discussion	603
Acknowledgments	607
References	608
<b>21. Interleukin-6 and Insulin Resistance</b>	<b>613</b>
Jeong-Ho Kim, Rebecca A. Bachmann, and Jie Chen	
I. Introduction	614
II. Insulin Signaling and Insulin Resistance	615
III. IL-6 and Insulin Resistance	619
IV. Conclusions	625
Acknowledgment	626
References	627

<b>22. Structure, Function, and Regulation of Insulin-Degrading Enzyme</b>	<b>635</b>
Raymond E. Hulse, Luis A. Ralat, and Wei-Jen Tang	
I. Introduction	636
II. Structure of IDE	637
III. The Regulation of IDE Activity	642
IV. Conclusion	645
Acknowledgments	645
References	645
<b>23. Modification of Androgen Receptor Function by IGF-1 Signaling: Implications in the Mechanism of Refractory Prostate Carcinoma</b>	<b>649</b>
Toshihiko Yanase and WuQiang Fan	
I. Androgen Receptor Signaling	651
II. IGF Signaling and Foxo-1	653
III. Interaction between AR and Insulin/IGF-1 Signaling	654
IV. Clinical Implications of Interactions between IGF-1 Signaling and AR	659
V. Conclusion	662
Acknowledgments	663
References	663
<b>24. Insulin-Like Growth Factor-2/Mannose-6 Phosphate Receptors</b>	<b>667</b>
Hesham M. El-Shewy and Louis M. Luttrell	
I. Introduction	668
II. The IGF-2/M6P Receptor	671
III. Functions of the IGF-2/M6P Receptor	678
IV. Conclusions	685
References	685
<b>25. Interactions of IGF-II with the IGF2R/Cation-Independent Mannose-6-Phosphate Receptor: Mechanism and Biological Outcomes</b>	<b>699</b>
J. Brown, E. Y. Jones, and B. E. Forbes	
I. Introduction	700
II. The Mechanism of the IGF2R:IGF-II Interaction	701
III. Conclusion	713
References	714
<i>Index</i>	<i>721</i>

# CONTENTS

<i>Contributors</i>	<i>xv</i>
<i>Preface</i>	<i>xxi</i>
<b>1. Enzymatic Formation of Anandamide</b>	<b>1</b>
Yasuo Okamoto, Kazuhito Tsuboi, and Natsuo Ueda	
I. The Transacylation–Phosphodiesterase Pathway for Anandamide Formation	2
II. NAT	4
III. NAPE-PLD	9
IV. Alternative Pathways Forming NAEs from NAPEs	15
V. Conclusions	18
References	19
<b>2. Organized Trafficking of Anandamide and Related Lipids</b>	<b>25</b>
Marla L. Yates and Eric L. Barker	
I. AEA and the Endocannabinoid System	26
II. AEA Transport	31
Acknowledgment	45
References	45
<b>3. Biosynthesis of Oleamide</b>	<b>55</b>
Gregory P. Mueller and William J. Driscoll	
I. Introduction	56
II. Fatty Acid Amide Messengers: Structural Considerations	56
III. Natural Occurrence of Oleamide	57
IV. Biologic Actions of Oleamide	58
V. Proposed Mechanisms for the Biosynthesis of Oleamide	59
VI. Oleamide Biosynthesis by Peptidylglycine Alpha-amidating Monooxygenase	60
VII. Discovery of Cytochrome <i>c</i> as an Oleamide Synthase	62
VIII. Cytochrome <i>c</i> also Catalyzes the Formation of Oleoylglycine and Other Long-Chain Fatty Acylamino Acids	64
IX. Proposal for an Oleamide Synthesome	66

X. Apoptosis: A Model for the Mechanism and Regulation of Oleamide Biosynthesis	67
XI. Considerations for the Investigation of Oleamide Biosynthesis	70
XII. Future Directions and Concluding Remarks	70
References	71
<b>4. Anandamide Receptor Signal Transduction</b>	<b>79</b>
Catherine E. Goodfellow and Michelle Glass	
I. Introduction	80
II. Cannabinoid Receptor 1	81
III. Cannabinoid Receptor 2	89
IV. Transient Receptor Potential Vanilloid 1	90
V. Evidence for Additional Receptors	92
VI. Concluding Remarks	98
References	99
<b>5. Is GPR55 an Anandamide Receptor?</b>	<b>111</b>
Andrew J. Brown and C. Robin Hiley	
I. $\Delta^9$ -Tetrahydrocannabinol, CB <sub>1</sub> , and CB <sub>2</sub> Receptors	112
II. Functional Evidence for Novel Cannabinoid Receptors	113
III. Genomics of G Protein-Coupled Cannabinoid Receptors	116
IV. The Orphan Receptor GPR55	117
V. Endogenous Ligands for GPR55	121
VI. GPR55 Cellular Signaling Pathways	123
VII. Interactions Between GPR55 and CB <sub>1</sub> Receptors	126
VIII. Conclusion: GPR55 as an Anandamide Receptor	128
References	133
<b>6. The Endocannabinoid System During Development: Emphasis on Perinatal Events and Delayed Effects</b>	<b>139</b>
Ester Fride, Nikolai Gobshtis, Hodaya Dahan, Aron Weller, Andrea Giuffrida, and Shimon Ben-Shabat	
I. Introduction	140
II. Early Gestation	141
III. Neural Development	146
IV. Postnatal Development	147
V. Effects of Developmental Manipulation of the ECS System on the Offspring	150
VI. Conclusions	152
Acknowledgments	153
References	153



<b>7. Cannabinoid Receptor CB<sub>1</sub> Antagonists: State of the Art and Challenges</b>	<b>159</b>
Maurizio Bifulco, Antonietta Santoro, Chiara Laezza, and Anna Maria Malfitano	
I. Introduction	160
II. Endocannabinoid System: Control of Energy Balance	161
III. Cannabinoid CB <sub>1</sub> Receptors and CB <sub>1</sub> Antagonists	162
IV. CB <sub>1</sub> Antagonists in the Treatment of Obesity and Related Comorbidities	169
V. Other Emerging Effects of CB <sub>1</sub> Antagonists	176
VI. Therapeutic Prospects	179
VII. Conclusions	180
Acknowledgments	181
References	181
<b>8. Novel Endogenous <i>N</i>-Acyl Glycines: Identification and Characterization</b>	<b>191</b>
Heather B. Bradshaw, Neta Rimmerman, Sherry S.-J. Hu, Sumner Burstein, and J. Michael Walker	
I. Historical View of Lipid Signaling Discoveries	192
II. The Identification of Endogenous Signaling Lipids with Cannabimimetic Activity	192
III. Identification of Additional <i>N</i> -Acyl Amides	193
IV. <i>N</i> -Arachidonoyl Glycine Biological Activity	194
V. <i>N</i> -Arachidonoyl Glycine Biosynthesis	194
VI. <i>N</i> -Palmitoyl Glycine Biological Activity	195
VII. <i>N</i> -Palmitoyl Glycine Biosynthesis	197
VIII. PalGly Metabolism	197
IX. Identification and Characterization of Additional Members of the <i>N</i> -Acyl Glycines	198
X. Biological Activity of Novel <i>N</i> -Acyl Glycines	200
XI. Conclusions	201
References	203
<b>9. The Endocannabinoid Anandamide: From Immunomodulation to Neuroprotection. Implications for Multiple Sclerosis</b>	<b>207</b>
Fernando G. Correa, Leyre Mestre, Fabián Docagne, José Borrell, and Carmen Guaza	
I. Introduction	208
II. AEA as a Neuroimmune Signal	212

III. Anandamide and Multiple Sclerosis	219
IV. Concluding Remarks	223
Acknowledgment	224
References	224
<b>10. Modulation of the Endocannabinoid-Degrading Enzyme Fatty Acid Amide Hydrolase by Follicle-Stimulating Hormone</b>	<b>231</b>
Paola Grimaldi, Gianna Rossi, Giuseppina Catanzaro, and Mauro Maccarrone	
I. Follicle-Stimulating Hormone: Signal Transduction and Molecular Targets	232
II. Sertoli Cells: Activities and Biological Relevance	237
III. Overview of the Endocannabinoid System	239
IV. The ECS in Sertoli Cells	241
V. Regulation of FAAH by FSH in Sertoli Cells	243
VI. FAAH Is an Integrator of Fertility Signals	244
VII. Conclusions	254
Acknowledgments	255
References	255
<b>11. Glucocorticoid-Regulated Crosstalk Between Arachidonic Acid and Endocannabinoid Biochemical Pathways Coordinates Cognitive-, Neuroimmune-, and Energy Homeostasis-Related Adaptations to Stress</b>	<b>263</b>
Renato Malcher-Lopes and Marcelo Buzzi	
I. Introduction	264
II. The Arachidonic Acid Cascade	266
III. Glucocorticoid-Mediated Inhibition of cPLA <sub>2</sub> -Dependent AA Release from Membrane Phospholipids	269
IV. Biosynthesis of the AA-Containing Endocannabinoids AEA and 2-AG	271
V. Nongenomic Glucocorticoid-Induced Activation of Endocannabinoid Biosynthesis	274
VI. Endocannabinoids Metabolization	278
VII. Crosstalk Between GCs and COX <sub>2</sub> in the Control of Neuroinflammation and Neuroprotection	282
VIII. Crosstalk Between GCs and COX <sub>2</sub> in the Control of Synaptic Plasticity and Learning Processes	285
IX. Coordination of GC-Mediated Control of the Neuroimmune Response and Energy Homeostasis Control	288
Acknowledgments	295
References	295

<b>12. Modulation of the Cys-Loop Ligand-Gated Ion Channels by Fatty Acid and Cannabinoids</b>	<b>315</b>
Li Zhang and Wei Xiong	
I. CB Receptor-Dependent and -Independent Effects of Endocannabinoids	316
II. Structure and Function of the Cys-Loop LGICs	317
III. Inhibition of 5-HT <sub>3</sub> Receptors by Cannabinoids	318
IV. Modulation of Gly Receptor Function by Cannabinoids	324
V. Inhibition of nACh Receptors by Endocannabinoids	328
VI. Modulation of GABA <sub>A</sub> Receptor Function by Fatty Acids	329
VII. Concluding Discussion	330
References	331
<b>13. Endogenous Cannabinoids and Neutrophil Chemotaxis</b>	<b>337</b>
Douglas McHugh and Ruth A. Ross	
I. Cellular Motility and Neutrophils	338
II. The Endogenous Cannabinoid System	339
III. Cannabinoids Modulate Cell Migration	342
IV. Endocannabinoid Effects on Basal Locomotion of Neutrophils	343
V. Endocannabinoid Effects on Induced Migration of Neutrophils	343
VI. Cannabinoid Receptor Expression in Neutrophils	344
VII. Inhibition of Induced Migration: Which Receptors are Involved?	345
VIII. Inhibitory Signal Transduction Mechanisms: Receptor Crosstalk	350
IX. Inhibitory Signal Transduction Mechanisms: Disruption of the Actin Cytoskeleton	351
X. Conclusion	356
References	357
<b>14. CB<sub>1</sub> Activity in Male Reproduction: Mammalian and Nonmammalian Animal Models</b>	<b>367</b>
Riccardo Pierantoni, Gilda Cobellis, Rosaria Meccariello, Giovanna Cacciola, Rosanna Chianese, Teresa Chioccarelli, and Silvia Fasano	
I. Introduction	368
II. Receptor Properties	368
III. Brain–Pituitary Axis	371
IV. Testis	374
V. Excurrent Duct System	379
VI. Concluding Remarks	382
References	382

<b>15. Anandamide and the Vanilloid Receptor (TRPV<sub>1</sub>)</b>	<b>389</b>
Attila Tóth, Peter M. Blumberg, and Judit Boczán	
I. Cannabinoid and Vanilloid Receptors	390
II. Biochemistry of Anandamide	392
III. Anandamide as Vanilloid Receptor (TRPV <sub>1</sub> ) Ligand	396
IV. Other Anandamide Receptors	404
V. Physiological Actions of Anandamide on TRPV <sub>1</sub>	404
VI. Future Directions	410
References	411
<b>16. Endocannabinoid System and Fear Conditioning</b>	<b>421</b>
Leonardo B. M. Resstel, Fabrício A. Moreira, and Francisco S. Guimarães	
I. Introduction	421
II. Fear Conditioning	423
III. Influence of Endocannabinoids on Fear Conditioning	426
IV. Brain Regions in which Endocannabinoids may Modulate Fear Conditioning	429
V. Conclusion	433
References	433
<b>17. Regulation of Gene Transcription and Keratinocyte Differentiation by Anandamide</b>	<b>441</b>
Nicoletta Pasquariello, Sergio Oddi, Marinella Malaponti, and Mauro Maccarrone	
I. Introduction	442
II. Epidermis	445
III. Transcriptional Control of Skin Differentiation	453
IV. Endocannabinoid System in Epidermis	455
V. Modulation of the Endocannabinoid System in Differentiating Keratinocytes	456
VI. Repression of Gene Transcription by Anandamide	457
VII. Conclusions	459
Acknowledgments	460
References	461
<b>18. Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer</b>	<b>469</b>
Gianfranco Alpini and Sharon DeMorrow	
I. Introduction	470
II. Changes in the Endocannabinoid System in Cancer	471

III. Antiproliferative Effects of Anandamide	473
IV. Effects of AEA on Migration, Invasion, and Angiogenesis	476
V. Targeting Degradation Enzymes of Cannabinoids as an Anticancer Therapy	479
VI. Tumor Promoting Effects of Anandamide	480
VII. Conclusions	480
Acknowledgments	481
References	481
<b>19. Use of Cannabinoids as a Novel Therapeutic Modality Against Autoimmune Hepatitis</b>	<b>487</b>
Rupal Pandey, Venkatesh L. Hegde, Narendra P. Singh, Lorne Hofseth, Uday Singh, Swapan Ray, Mitzi Nagarkatti, and Prakash S. Nagarkatti	
I. Introduction	488
II. The Endogenous Cannabinoid System	489
III. The Biosynthesis of Endocannabinoids	490
IV. Endocannabinoid System is Autoprotective	490
V. Autoimmune Hepatitis	492
VI. Treatment Drawbacks	494
VII. Cannabinoid/Endocannabinoid System in Hepatitis	494
VIII. Conclusions and Future Directions	499
Acknowledgments	500
References	500
<i>Index</i>	505

# CONTENTS

<i>Contributors</i>	xv
<i>Preface</i>	xix
<b>1. Models of Depression</b>	<b>1</b>
Catharine H. Duman	
I. Introduction	2
II. General Considerations in Modeling Depression	2
III. Stress and Models of Depression	4
IV. Models	6
V. Concluding Remarks	15
References	15
<b>2. Astrocytes in the Amygdala</b>	<b>23</b>
Ryan T. Johnson, S. Marc Breedlove, and Cynthia L. Jordan	
I. The Amygdala	24
II. Glia	25
III. Amygdala Glia and Disease	26
IV. Amygdala Glia and Hormones	33
V. Conclusions	37
Acknowledgments	38
References	38
<b>3. Limbic Effects of High-Frequency Stimulation of the Subthalamic Nucleus</b>	<b>47</b>
Yasin Temel	
I. Introduction	48
II. Discussion	56
III. Conclusion	57
Acknowledgments	58
References	58

<b>4. Hippocampal Mossy Fiber Synaptic Transmission and Its Modulation</b>	<b>65</b>
Katsunori Kobayashi	
I. Introduction	65
II. Conclusion	77
References	78
<b>5. Xenobiotics in the Limbic System—Affecting Brain’s Network Function</b>	<b>87</b>
Ralf P. Meyer, Georgios Pantazis, Nina Killer, Carolin Bürck, Ricarda Schwab, Monika Brandt, Rolf Knoth, and Marcel Gehlhaus	
I. Introduction	88
II. Xenobiotic Uptake and the Limbic System	89
III. The Main Players	91
IV. Molecular Circuits in the Limbic System	93
V. Downstream Effects from the Blood–Brain Barrier to the Limbic System	95
VI. Conclusions and Future Directions	101
Acknowledgments	102
References	102
<b>6. Brain Plasticity after Ischemic Episode</b>	<b>107</b>
Galyna G. Skibo and Alexander G. Nikonenko	
I. Mechanisms of Brain Ischemic Injury	107
II. Mechanisms of Adult Brain Plasticity	114
III. Postischemic Brain Plasticity	116
References	121
<b>7. Hypothalamic Inflammation and Obesity</b>	<b>129</b>
Elíana P. Araújo, Márcio A. Torsoni, and Lício A. Velloso	
I. Introduction	129
II. Hypothalamic Control of Feeding and Energy Expenditure	130
III. Nutrient-Induced Dysfunction of the Hypothalamus	136
IV. Hypothalamic Resistance to Anorexygenic Signals	137
V. Concluding Remarks	139
Acknowledgments	139
References	139

<b>8. The Role of Functional Postsynaptic NMDA Receptors in the Central Nucleus of the Amygdala in Opioid Dependence</b>	<b>145</b>
Michael J. Glass	
I. Introduction	146
II. Opioids and Dependence	147
III. Glutamate Systems and Opioid Dependence	148
IV. The Central Nucleus and Dependence	149
V. The Synaptic Relationship Between NMDA and $\mu$ -Opioid Receptors in the CeA	152
VI. Deletion of Postsynaptic NR1 in Central Amygdala Neurons Attenuates Opioid Withdrawal-Induced Place Aversion	154
VII. Does the CeA Selectively Participate in the Conditioned Aversive Properties of Opioid Withdrawal?	155
VIII. Conclusion	158
References	160
<b>9. Hippocampal Kainate Receptors</b>	<b>167</b>
Erik B. Bloss and Richard G. Hunter	
I. Introduction	168
II. Structure of Kainate Receptors	169
III. Anatomical Localization of KARs in the Hippocampal Formation	171
IV. Electrophysiological Functions of KARs in Hippocampal Synapses	175
V. KARs in Disease	177
VI. Conclusion	179
References	180
<b>10. Role of Neurotrophic Factors in Behavioral Processes: Implications for the Treatment of Psychiatric and Neurodegenerative Disorders</b>	<b>185</b>
Marie-Christine Pardon	
I. Introduction	186
II. Cognition-Enhancing Effects of Neurotrophins	187
III. Neurotrophins Mediate Aggressive and Defensive Behavior	189
IV. Involvement of Neurotrophins in Anxiety-Like Behavior	190
V. Role of Neurotrophins in Rewarding and Addictive Behavior	191
VI. Neurotrophins Facilitate Adaptation to Stress	192
VII. Neurotrophins: A Therapeutic Target for the Treatment of Brain Disorders?	194
References	194



<b>11. Postnatal Development of Hypothalamic Leptin Receptors</b>	<b>201</b>
Elizabeth C. Cottrell, Julian G. Mercer, and Susan E. Ozanne	
I. Introduction	202
II. The Leptin System	203
III. Developmental Roles of Leptin	205
IV. Developmental Programming: Role of Altered Neonatal Leptin Signaling	210
V. Conclusions and Future Directions	212
Acknowledgments	214
References	214
<b>12. Regulation of Hippocampal Synaptic Plasticity by Estrogen and Progesterone</b>	<b>219</b>
Michael R. Foy, Michel Baudry, Garnik K. Akopian, and Richard F. Thompson	
I. Introduction	220
II. Estrogen and Hippocampus	221
III. Estrogen, NMDA, and AMPA Receptor Regulation	222
IV. Estrogen and Hippocampal LTP	225
V. Estrogen and Hippocampal LTD	230
VI. Progesterone and Hippocampus	230
VII. Progesterone and Progesterone Receptors	232
VIII. Progesterone and Hippocampal LTP and LTD	232
IX. Conclusions	233
Acknowledgments	236
References	236
<b>13. Hormones and Sexual Reward</b>	<b>241</b>
Raúl G. Paredes	
I. Introduction	242
II. Reward	242
III. Conditioned Place Preference	244
IV. Hormones and CPP	246
V. Reward and Sexual Behavior	251
VI. Conclusion	256
Acknowledgments	256
References	256

<b>14. Sex Steroids and Acetylcholine Release in the Hippocampus</b>	<b>263</b>
Dai Mitsushima	
I. Role of Acetylcholine in the Hippocampus	264
II. ACh Release in the Hippocampus Is Sex-Specific	265
III. Neural Control of Septohippocampal Cholinergic Neurons	266
IV. Circulating Sex Steroids Activate ACh Release	267
V. Activational Effect Is Sex-Specific	268
VI. Sexual Differentiation Fates the Sex-Specific Activational Effect	269
VII. Interaction with Environmental Conditions	269
VIII. Interaction with Spontaneous Behaviors	271
IX. Activational Effects and Alzheimer's Disease	271
X. Conclusions	272
Acknowledgments	272
References	273
<b>15. Estradiol and GABAergic Transmission in the Hippocampus</b>	<b>279</b>
Tomasz Wójtowicz and Jerzy W. Mozzrymas	
I. Introduction	280
II. Estradiol and GABA <sub>A</sub> R Function	281
III. Estradiol and GABAergic Transmission During Development	282
IV. Estradiol and GABAergic Transmission in Mature Animals	287
V. Mechanisms of Estradiol Action	289
VI. Conclusions and Future Directions	293
Acknowledgments	294
References	294
<b>16. Transcriptional Regulation of Hypothalamic Corticotropin-Releasing Factor Gene</b>	<b>301</b>
Kazunori Kageyama and Toshihiro Suda	
I. Introduction	302
II. Regulatory Elements on Hypothalamic CRF Gene	302
III. Conclusion	311
Acknowledgments	314
References	314
<b>17. Estrogen in the Limbic System</b>	<b>319</b>
Gert J. ter Horst	
I. Estrogen Synthesis and Actions	320
II. Estrogen Receptors	321
III. Anatomy of the Limbic System	322

IV. Distribution of Estrogen Receptors in the Limbic System	323
V. Estrogen and ER $\beta$ Expression	323
VI. Affective Disorders and Gender	324
VII. Estrogen in Hippocampus and Amygdala	325
VIII. Cyclic Estrogen Administration and Stress	326
IX. Estrogen, Stress, and Neuroplasticity	328
X. Recovery After Chronic Stress; Effect of Estrogen and Antidepressants	329
XI. Conclusion	331
References	333
<b>18. Corticotropin-Releasing Hormone and Arginine Vasopressin in Depression: Focus on the Human Postmortem Hypothalamus</b>	<b>339</b>
Ai-Min Bao and Dick F. Swaab	
I. Introduction	340
II. The HPA-Axis as the Final Common Pathway in Depression	342
III. The AVP Hypothesis of Depression	348
IV. Depression in Alzheimer's Disease	356
V. Conclusions	357
Acknowledgments	358
References	359
<b>19. Postnatal Ontogeny of the Glucocorticoid Receptor in the Hippocampus</b>	<b>367</b>
Anastasia Galeeva, Markku Peltö-Huikko, Svetlana Pivina, and Natalia Ordyan	
I. Introduction	368
II. Postnatal Development of the HPA Axis and the Stress-Hyporesponsive Period	369
III. Postnatal Expression of Corticosteroid Receptors in the Rat Hippocampus	373
IV. Effect of Prenatal Stress on the Expression of the GR in the Hippocampus During Postnatal Development	379
References	382
<b>20. Mineralocorticoid and Glucocorticoid Receptors in Hippocampus: Their Impact on Neurons Survival and Behavioral Impairment After Neonatal Brain Injury</b>	<b>391</b>
Justyna Rogalska	
I. Introduction	392
II. Corticosteroid Receptors Properties	394

---

III. MR and GR Under Development of the Hippocampus	396
IV. Detrimental Effects of Hippocampal Glucocorticoid Receptor Activation	396
V. Neuroprotective Role of MR Overexpression in Damaged Hippocampus	401
VI. The Effect of Temperature on Hypoxia/Ischemia-Induced Changes in MR and GR Expression	405
VII. The Long-Term Consequences of Alterations in MR and GR Receptors After Neonatal Brain Injury	407
VIII. Conclusion	411
References	412
<b>21. Glucocorticoids and Lithium in Adult Hippocampal Neurogenesis</b>	<b>421</b>
Shuken Boku, Shin Nakagawa, and Tsukasa Koyama	
I. Introduction	422
II. Differential Steps of Adult Hippocampal Neurogenesis	422
III. Stress and Glucocorticoids Actions on Adult Hippocampal Neurogenesis	424
IV. Lithium Action on Adult Hippocampal Neurogenesis	425
V. Concluding Remarks	426
Acknowledgments	428
References	428
<i>Index</i>	433

# CONTENTS

<i>Contributors</i>	<i>xv</i>
<i>Preface</i>	<i>xxi</i>
<b>1. Functional Neuronal Processing of Human Body Odors</b>	<b>1</b>
Johan N. Lundström and Mats J. Olsson	
I. The Microsmatic Fallacy	2
II. Human Body Odor Perception and Production	3
III. Central Processing of Body Odors	4
IV. Neuronal Processing of the Smell of Fear	7
V. Are Body Odors Processed by the Main Olfactory System?	12
VI. Kin Recognition via Body Odors	15
VII. The Stimulus Delivery Problem	16
VIII. Conclusion	17
Acknowledgments	18
References	18
<b>2. Female Perception of Male Body Odor</b>	<b>25</b>
Mark J. T. Sergeant	
I. Olfaction in Humans	26
II. Sex Differences in Sensitivity to Body Odor	29
III. The Physiological and Behavioral Impact of Male Odor on Females	32
IV. The Effects of Odor on Mate Choice	36
V. Conclusions	39
References	40
<b>3. Current Issues in the Study of Androstenes in Human Chemosignaling</b>	<b>47</b>
Jan Havlicek, Alice K. Murray, Tamsin K. Saxton, and S. Craig Roberts	
I. Introduction	48
II. Biochemistry of Androstenes	49
III. Psychophysical Research Using Androstenes	52
IV. Psychological Effects	58
V. Discussion	68
Acknowledgments	74
References	75
	vii

<b>4. Mammary Odor Cues and Pheromones: Mammalian Infant-Directed Communication about Maternal State, Mammae, and Milk</b>	<b>83</b>
Benoist Schaal	
I. Introduction: Sensory Guidance to the Milk Resource for Inexperienced, Fragile Newborns	84
II. Evolution and General Functions of Mammary Odor Cues	85
III. What Is in a Scent? Informational Intricacy in Mammary Odor	87
IV. Pan-Mammalian Distribution of Mammary Odor Cues and Signals	91
V. Regulation of Mammary Odor Cues and Pheromones	116
VI. Conclusions and Prospects	119
Acknowledgments	122
References	122
<b>5. Exposure to Female Pheromones During Pregnancy Causes Postpartum Anxiety in Mice</b>	<b>137</b>
Caroline M. Larsen and David R. Grattan	
I. Materials and Methods	139
II. Results	141
III. Discussion	146
References	148
<b>6. Major Urinary Protein Regulation of Chemical Communication and Nutrient Metabolism</b>	<b>151</b>
Yingjiang Zhou and Liangyou Rui	
I. Introduction	152
II. MUP Structure and Polymorphism	152
III. MUP Regulation of Chemical Communication	154
IV. MUP Regulation of Nutrient Metabolism	156
V. Conclusions and Future Directions	159
Acknowledgments	160
References	160
<b>7. Chemosensory Function of the Amygdala</b>	<b>165</b>
Nicolás Gutiérrez-Castellanos, Alino Martínez-Marcos, Fernando Martínez-García, and Enrique Lanuza	
I. Introduction	168
II. Compartmentalization of the Chemosensory Amygdala	169
III. Functional Anatomy of the Chemosensory Amygdala	180
IV. Evolutionary Relevance of the Chemosensory Amygdala	186
V. Conclusions and Future Directions	189

Acknowledgments	189
References	189
<b>8. TRPC Channels in Pheromone Sensing</b>	<b>197</b>
Kirill Kiselyov, Damian B. van Rossum, and Randen L. Patterson	
I. Pheromone Sensing Circuits	198
II. TRPC2 and Pheromone Sensing	199
III. TRPC Activation Mechanisms	200
IV. Perspectives: The “DAG Effect” and Beyond	207
Acknowledgments	209
References	210
<b>9. Alarm Pheromones—Chemical Signaling in Response to Danger</b>	<b>215</b>
François J. Verheggen, Eric Haubruge, and Mark C. Mescher	
I. Introduction	216
II. Alarm Pheromones in Insects	217
III. Alarm Pheromones in Marine Invertebrates	227
IV. Alarm Pheromones in Fish	228
V. Alarm Pheromones in Mammals	229
VI. Alarm Signals in Plants	230
VII. Conclusion: Potential Applications of Alarm Pheromones	231
References	232
<b>10. Odorant-Binding Proteins in Insects</b>	<b>241</b>
Jing-Jiang Zhou	
I. Introduction	241
II. Diversity of Odorant-Binding Proteins	243
III. Pheromone and Ligand Binding	250
IV. Structure Aspects	259
V. Function of OBPs	262
VI. Conclusion	264
References	265
<b>11. <i>Drosophila</i> CheB proteins Involved in Gustatory Detection of Pheromones Are Related to a Human Neurodegeneration Factor</b>	<b>273</b>
Claudio W. Pikielny	
I. Introduction	274
II. <i>Drosophila</i> CheBs Are Expressed in a Variety of Sex-Specific Subsets of Taste Hairs that May Be Specialized in Pheromone Detection	275

III. CheB42a Is Required for Normal Response to Female-Specific Pheromones	277
IV. CheBs Belong to the ML Superfamily of Lipid-Binding Proteins and Share Functionally Important Sequences with GM2-Activator Protein, an Essential Protein of Human Neurons	279
V. CheBs Likely Function as Gustatory-Specific Pheromone-Binding Proteins	281
VI. Models for the Function of CheBs in Gustatory Detection of Pheromones	283
VII. Conclusions and Future Directions	285
Acknowledgments	285
References	285
<b>12. Volatile Signals During Pregnancy</b>	<b>289</b>
Stefano Vaglio	
I. Introduction	290
II. Mother Recognition	291
III. Mother–Infant Interactions	295
IV. Chemical Profile of Volatile Compounds During Pregnancy	297
V. Conclusions and Future Directions	298
Acknowledgments	301
References	301
<b>13. Olfactory Sensitivity: Functioning in Schizophrenia and Implications for Understanding the Nature and Progression of Psychosis</b>	<b>305</b>
Warrick J. Brewer and Christos Pantelis	
I. Introduction: Overview	306
II. Structural Organisation of Olfactory Function	307
III. Olfactory Identification Deficits in Schizophrenia	309
IV. Olfactory Sensitivity Through Development	310
V. Summary and Future Directions	323
Acknowledgments	324
References	324
<b>14. Olfactory Systems in Mate Recognition and Sexual Behavior</b>	<b>331</b>
Matthieu Keller, Delphine Pillon, and Julie Bakker	
I. Introduction	332
II. A Short Introduction to the Organization of the Accessory and Main Olfactory Subsystems	333
III. Both MOS and AOS Are Functionally Involved in Pheromonal Processing	336



IV. Involvement of Both Olfactory Systems in the Control of Mate Discrimination and Sexual Behavior	340
V. General Conclusions	344
Acknowledgments	345
References	345
<b>15. Communication by Olfactory Signals in Rabbits: Its Role in Reproduction</b>	<b>351</b>
Angel I. Melo and Gabriela González-Mariscal	
I. Introduction	352
II. Communication by Chemical Signals	352
III. Other Sources of Chemical Signals	363
IV. Conclusions and Future Directions	364
Acknowledgments	367
References	367
<b>16. Chemical Communication and Reproduction in the Gray Short-Tailed Opossum (<i>Monodelphis Domestica</i>)</b>	<b>373</b>
John D. Harder and Leslie M. Jackson	
I. Chemical Communication and Mammalian Reproduction	374
II. Reproductive Cycles and Seasonal Breeding in Female Mammals	375
III. The Gray Short-Tailed Opossum: A Model for Pheromonal Control of Reproduction	377
IV. Olfactory Behavior; Sources and Reception of Chemical Signals	379
V. Male Estrus-Inducing Pheromone in Opossums	384
VI. Endocrinology of Reproductive Activation	386
VII. Reproductive and Behavioral Ecology of Opossums	391
VIII. Summary and Conclusions	393
Acknowledgments	394
References	394
<b>17. Pheromones in a Superorganism: From Gene to Social Regulation</b>	<b>401</b>
C. Alaux, A. Maisonnasse, and Y. Le Conte	
I. Introduction	402
II. Physiological and Behavioral Regulation	404
III. Gene Regulation	408
IV. Social Regulation	413
V. Conclusions and Future Directions	415
Acknowledgments	418
References	418

<b>18. Unraveling the Pheromone Biosynthesis Activating Neuropeptide (PBAN) Signal Transduction Cascade that Regulates Sex Pheromone Production in Moths</b>	<b>425</b>
Shogo Matsumoto, Atsushi Ohnishi, Jae Min Lee, and J. Joe Hull	
I. Introduction	426
II. Physiological Background	427
III. Molecular Background: Essential Components of <i>B. mori</i> Sex Pheromone Production	430
IV. Essential Components and Mechanisms of the <i>B. mori</i> PBAN Signal Transduction Cascade	435
V. Model for PBAN Signaling in <i>B. mori</i>	439
VI. Conclusions	440
Acknowledgments	441
References	441
<b>19. Pheromones in Social Wasps</b>	<b>447</b>
Bruschini Claudia, Cervo Rita, and Turillazzi Stefano	
I. Introduction	448
II. Nestmate Recognition Pheromones	451
III. Queen Pheromones and Fertility/Rank Pheromones	461
IV. Sex Pheromones	463
V. Alarm Pheromones	466
VI. Trail and Substrate Marking Pheromones	471
VII. Defense Allomones	473
VIII. Future Directions	476
Acknowledgments	477
References	477
<b>20. New Pheromones and Insect Control Strategies</b>	<b>493</b>
Gadi V. P. Reddy and Angel Guerrero	
I. Introduction	494
II. Mating Disruption in Insect Control Programs	494
III. Pheromone Antagonists as Chemical Communication Inhibitors	501
IV. Use of Pheromones with Plant-Based Volatiles	504
V. Attract-and-Kill	508
VI. Push–Pull Strategies	509
VII. Conclusions and Outlook	510
Acknowledgments	510
References	511

<b>21. Pheromones and Exocrine Glands in Isoptera</b>	<b>521</b>
Ana Maria Costa-Leonardo and Ives Haifig	
I. Introduction	522
II. Pheromonal Communication	523
III. Principal Exocrine Glands: Source of Pheromones	524
IV. Frontal Gland	526
V. Mandibular Glands	530
VI. Salivary or Labial Glands	531
VII. Sternal Gland	534
VIII. Tergal Gland	538
IX. Termite Recognition Pheromones	540
X. Concluding Remarks	541
Acknowledgment	542
References	542
<b>22. Aphid Pheromones</b>	<b>551</b>
Sarah Y. Dewhurst, John A. Pickett, and Jim Hardie	
I. Introduction	552
II. Semiochemicals	553
III. Aphid Alarm Pheromones	554
IV. Aphid Sex Pheromone	555
V. Other Aphid Pheromones	566
VI. Conclusion	567
References	567
<b>23. Recent Advances in Methyl Eugenol and Cue-Lure Technologies for Fruit Fly Detection, Monitoring, and Control in Hawaii</b>	<b>575</b>
Roger I. Vargas, Todd E. Shelly, Luc Leblanc, and Jaime C. Piñero	
I. Introduction	576
II. Insect Pheromones and Parapheromones	577
III. Fruit Flies and Economic Importance	578
IV. Relationship Between Male Behavior and ME and C-L/RK	580
V. Technology Development and Transfer Through the Hawaii Area-Wide Pest Management Program	583
VI. Environmental Impact of ME and C-L/RK	587
VII. Conclusions and Future Applications	589
Acknowledgments	589
References	590

---

<b>24. Oviposition Pheromones in Haematophagous Insects</b>	<b>597</b>
T. Seenivasagan and R. Vijayaraghavan	
I. Introduction	598
II. Origin of Oviposition Pheromones	599
III. Habitat Associated Kairomones	603
IV. Microbial Volatiles Eliciting Oviposition	604
V. Parapheromones Mediating Oviposition	605
VI. Predator/Prey Released Kairomones	607
VII. Oviposition Cues of Blood Feeding Bugs	608
VIII. Oviposition Cues of Veterinary Insects	610
IX. Synthesis of Oviposition Pheromones	611
X. Evaluation of Oviposition Pheromones	612
XI. Oviposition Traps and Baits for Monitoring and Control	616
XII. Concluding Remarks	619
Acknowledgements	620
References	620
 <i>Index</i>	 <i>631</i>

# CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xvii</i>
<b>1. Evolution of Genes for Incretin Hormones and their Receptors</b>	<b>1</b>
David M. Irwin	
I. Introduction	2
II. Evolution on Incretin Hormone Genes	5
III. Evolution of Incretin Hormone Receptor Genes	12
IV. Evolution of Incretins	15
Acknowledgments	16
References	17
<b>2. Pleiotropic Actions of the Incretin Hormones</b>	<b>21</b>
Christopher H. S. McIntosh, Scott Widenmaier, and Su-Jin Kim	
I. Introduction	22
II. GIP and GLP-1 Actions: Hormonal and Neuronal Pathways	24
III. Effects of GIP and GLP-1 on Early Events During Feeding	27
IV. Effects of Incretins on Functions of the Endocrine Pancreas	28
V. Effects of GLP-1 on Food Intake and Satiety	44
VI. Gastrointestinal Effects of GIP and GLP-1	46
VII. Cardiovascular Effects of GIP and GLP-1	48
VIII. Effects of GIP and GLP-1 on Nutrient Storage and Flux	51
IX. Effects of GIP and GLP-1 on Bone	54
X. The Future	55
Acknowledgments	56
References	56
<b>3. Dietary Effects on Incretin Hormone Secretion</b>	<b>81</b>
Tongzhi Wu, Christopher K. Rayner, Karen Jones, and Michael Horowitz	
I. Introduction	82
II. Physiology of the Incretin Hormones	82
III. Dietary Influence on Incretin Hormone Secretion	85
IV. Mechanisms by Which Nutrients Stimulate Incretin Release	92
V. Incretin Responses in Obesity and Diabetes	97

VI. Therapeutic Implications	98
VII. Conclusions	100
Acknowledgments	101
References	101
<b>4. K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease</b>	<b>111</b>
Young Min Cho and Timothy J. Kieffer	
I. History of K-cells and GIP	112
II. The GIP Gene and Regulation of its Expression	115
III. Anatomical Localization and Development of K-cells	117
IV. Secretion, Degradation, and Elimination of GIP	120
V. Biological Actions of GIP	126
VI. GIP and K-cells in Health and Disease	128
VII. Clinical Application of GIP and K-cells	133
References	135
<b>5. The Emerging Role of Promiscuous 7TM Receptors as Chemosensors for Food Intake</b>	<b>151</b>
Petrine Wellendorph, Lars Dan Johansen, and Hans Bräuner-Osborne	
I. Introduction	153
II. Family C Receptors as Promiscuous Sensors for L- $\alpha$ -Amino acids, Peptides, Divalent cations, and Carbohydrates	153
III. Family A Receptors as Promiscuous Sensors for Peptone and Free Fatty Acids (FFAs)	164
IV. Therapeutic Perspectives	174
Acknowledgments	175
References	175
<b>6. Central Regulation of Glucose-Dependent Insulinotropic Polypeptide Secretion</b>	<b>185</b>
Maria P. Yavropoulou and John G. Yovos	
I. Introduction	186
II. Structure and Action of GIP	186
III. Regulation of GIP Secretion	187
IV. Neural Regulation of GIP Secretion	188
V. The Role of Autonomic Nervous System	188
VI. Concluding Remarks	196
References	196

<b>7. Incretin Hormone Secretion Over the Day</b>	<b>203</b>
Bo Ahrén, Richard D. Carr, and Carolyn F. Deacon	
I. Introduction	204
II. GIP and GLP-1 Secretion After Meal Ingestion	204
III. Regulation of GIP and GLP-1 Secretion	206
IV. Mechanisms of GIP and GLP-1 Secretion	209
V. GIP and GLP-1 Secretion Over the Day	209
VI. Incretin Hormone Secretion in Glucose Intolerance and Disease States	211
VII. GIP and GLP-1 Secretion in Fasting State	214
VIII. Conclusion and Perspective	215
Acknowledgments	216
References	216
<b>8. Using the Lymph Fistula Rat Model to Study Incretin Secretion</b>	<b>221</b>
Stephanie M. Yoder, Tammy L. Kindel, and Patrick Tso	
I. Introduction	222
II. The Incretin Hormones	223
III. Anatomy and Physiology of the Gastrointestinal and Lymphatic Systems	227
IV. The Lymph Fistula Model	229
V. Using the Lymph Fistula Rat Model to Study Incretin Secretion	232
VI. Concluding Remarks and Future Directions	242
Acknowledgments	244
References	244
<b>9. Structural Basis for Ligand Recognition of Incretin Receptors</b>	<b>251</b>
Christina Rye Underwood, Christoph Parthier, and Steffen Reedtz-Runge	
I. G-Protein-Coupled Receptors	252
II. The GLP-1 Receptor	254
III. The GIP Receptor	267
IV. Common and Divergent Features of GLP-1R and GIPR Ligand Binding	271
References	274
<b>10. Epac2-Dependent Rap1 Activation and the Control of Islet Insulin Secretion by Glucagon-Like Peptide-1</b>	<b>279</b>
Colin A. Leech, Oleg G. Chepurny, and George G. Holz	
I. Introduction	280
II. PKA and Epac2 Regulate Insulin Secretion from $\beta$ Cells	280
III. Epac2 Activates Rap1 GTPase	283
IV. Rap1 Effectors and Their Potential Roles in the Control of GSIS	285

V. Interactions of Epac2 with Secretory Granule-Associated Proteins	294
VI. Conclusions	296
Acknowledgment	297
References	297
<b>11. Central GLP-1 Actions on Energy Metabolism</b>	<b>303</b>
Douglas A. Velásquez, Daniel Beiroa, María J. Vázquez, Amparo Romero, Miguel López, Carlos Diéguez, and Ruben Nogueiras	
I. Introduction	304
II. CNS Glucagon-Like Peptide 1 and Energy Intake	305
III. CNS Glucagon-Like Peptide 1 and Glucose Metabolism	308
IV. CNS Glucagon-Like Peptide 1 and Lipid Metabolism	310
V. Future Directions	311
Acknowledgments	313
References	313
<b>12. Glucagon-Like Peptide-1: Gastrointestinal Regulatory Role in Metabolism and Motility</b>	<b>319</b>
Per M. Hellström	
I. Introduction	320
II. GLP-1 in Metabolism	321
III. GLP-1 in Satiety	323
IV. GLP-1 in GI Motility	324
V. GLP-1 in Perspective	327
Acknowledgments	327
References	328
<b>13. The Role of GLP-1 in Neuronal Activity and Neurodegeneration</b>	<b>331</b>
Christian Hölscher	
I. A Causal Link Between Diabetes and Alzheimer's Disease	332
II. An Insulin-Supporting Messenger: Glucagon-Like Peptide-1	334
III. GLP-1 Analogues Have Neuroprotective Effects in Mouse Models of AD	342
IV. Many Other Growth Factors Show Neuroprotective Effects	346
Acknowledgment	347
References	347
<b>14. Wnt and Incretin Connections</b>	<b>355</b>
Custodia García-Jiménez	
I. What Are Incretins, What They Do, Where, and How	356
II. WNTs: What They Are and What They Do	360
III. WNT/ $\beta$ -catenin Increases the Synthesis of Incretins	364



---

IV. Does WNT Influence Incretin Secretion?	369
V. Does WNT Influence Incretin Receptors and/or Their Signaling?	370
VI. Do Incretins Influence Wnt Signaling? GLP-1 Uses WNT Effectors in Pancreas	371
VII. What is the Meaning of the Wnt–Incretin Interplay for Health and Disease?	372
VIII. Perspectives	375
Acknowledgments	377
References	378
<b>15. Incretin-Based Therapy and Type 2 Diabetes</b>	<b>389</b>
Kristine J. Hare and Filip K. Knop	
I. Introduction	390
II. The Incretin Hormones	392
III. Incretin Hormones in Type 2 Diabetes	396
IV. Incretin-Based Therapy	397
V. Conclusion and Perspectives	404
References	405
<b>16. GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders</b>	<b>415</b>
Unmesh Shah and Timothy J. Kowalski	
I. Introduction	416
II. GPR119 Receptor Expression	418
III. GPR119 Signaling and Deorphanization	419
IV. GPR119 Agonism and Glucose Homeostasis	420
V. GPR119 Agonists: Medicinal Chemistry	423
VI. Conclusions	441
Acknowledgments	441
References	442
<i>Index</i>	449

# CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xvii</i>
<b>1. Activin Receptor-Like Kinase and the Insulin Gene</b>	<b>1</b>
Rie Watanabe	
I. Introduction	2
II. TGF- $\beta$ Family Receptors: ALK	3
III. Activin Isoforms A, B, and AB	5
IV. Nodal	9
V. Insulin Gene Regulation	9
VI. Conclusion	15
Acknowledgments	16
References	16
<b>2. Crystal Structure of Activin Receptor Type IIB Kinase Domain</b>	<b>29</b>
Seungil Han	
I. Introduction	30
II. Type I Receptor Kinase Domain Structures	31
III. 3D Structure of ActRIIB	32
IV. Conclusion	36
References	36
<b>3. Activin/Nodal Signaling and Pluripotency</b>	<b>39</b>
Zhenzhi Chng, Ludovic Vallier, and Roger Pedersen	
I. Introduction	40
II. Conclusion	51
References	52
<b>4. Intracrine Signaling Mechanisms of Activin A and TGF-<math>\beta</math></b>	<b>59</b>
Olav A. Gressner	
I. Common TGF- $\beta$ and Activin A Signaling and Target Genes: Focusing on CTGF/CCN2	60

II. The Early Response to Cellular Stress: Intracellular Activation of TGF- $\beta$	61
III. Continuous Low-Level Activation of Activin A/TGF- $\beta$ Target Genes	63
IV. Intracrine Signaling: General Aspects	65
V. Intracrine Signaling of TGF- $\beta$ : The Stimulatory Pathway	66
VI. Intracrine Signaling of TGF- $\beta$ : The Inhibitory Pathway	70
VII. Intracrine Activin A Signaling	72
VIII. Conclusion	73
References	74
<b>5. Negative Regulation of Activin Signal Transduction</b>	<b>79</b>
Sun-Cheol Choi and Jin-Kwan Han	
I. Introduction	80
II. Extracellular Antagonists	82
III. Negative Regulation of Activin Receptor Function	85
IV. Inhibitory Smads	89
V. Interfering with Smad Function	90
VI. Negative Regulation of Gene Transcription	94
VII. Conclusions	97
Acknowledgments	98
References	98
<b>6. Antagonism of Activin by Activin Chimeras</b>	<b>105</b>
Uwe Muenster, Radhika Korupolu, Ratindra Rastogi, Jessica Read, and Wolfgang H. Fischer	
I. Introduction	106
II. The Activin/BMP Receptor System	107
III. Design of Chimeras	115
IV. Assessment of Binding and Biological Properties of Chimeras	116
V. Summary, Conclusions, and Future Directions	121
Acknowledgments	123
References	123
<b>7. Activins and Cell Migration</b>	<b>129</b>
Hong-Yo Kang and Chih-Rong Shyr	
I. Introduction	130
II. Molecular Mechanism of Activin Signaling Regulated Cell Migration	132
III. The Role of Activins in the Regulation of Tumor Cell Migration and Metastasis	134
IV. The Role of Activins in the Modulation of Immune Cell Migration	139
V. Conclusion and Future Prospective	142
Acknowledgments	143
References	144

<b>8. The Synthesis and Secretion of Inhibins</b>	<b>149</b>
Kelly L. Walton, Yogeshwar Makanji, David M. Robertson, and Craig A. Harrison	
I. Introduction	150
II. Inhibin Expression and Regulation	151
III. Expression Profile of Inhibin in Human Tissues	155
IV. Inhibin Assembly	159
V. Circulating Inhibin Forms	164
VI. Concluding Remarks	170
References	171
<b>9. Multifunctional Roles of Activins in the Brain</b>	<b>185</b>
Hiroshi Ageta and Kunihiro Tsuchida	
I. Introduction	186
II. Expression Pattern of Activin and Activin Receptor in the Brain	187
III. Activin Receptor and its Regulatory Proteins	188
IV. Functions of Activins in the CNS	189
V. Conclusion and Perspectives	200
Acknowledgments	201
References	201
<b>10. The Role of Activin/Nodal and Wnt Signaling in Endoderm Formation</b>	<b>207</b>
Catherine Payne, Jason King, and David Hay	
I. Introduction	208
II. TGF $\beta$ Signaling	209
III. WNT/ $\beta$ -Catenin Signaling	210
IV. Applied Biology	212
V. Conclusions	214
Acknowledgments	214
References	214
<b>11. Activin in Glucose Metabolism</b>	<b>217</b>
Osamu Hashimoto and Masayuki Funaba	
I. Introduction	218
II. Activin Activity in Insulin-Producing and Insulin-Sensitive Tissues	219
III. Activin in Adipose Tissue Inflammation	225
IV. Conclusions and Future Directions	226
Acknowledgments	228
References	228

<b>12. Activin in Humoral Immune Responses</b>	<b>235</b>
Kenji Ogawa and Masayuki Funaba	
I. Introduction	236
II. Activin A in Th2 Cells	237
III. Activin A in B Cells	239
IV. Activin A in Macrophages	240
V. Activin A in Mast Cells	242
VI. Conclusions and Future Directions	246
References	248
<b>13. The Regulation and Functions of Activin and Follistatin in Inflammation and Immunity</b>	<b>255</b>
Mark P. Hedger, Wendy R. Winnall, David J. Phillips, and David M. de Kretser	
I. Introduction	256
II. Molecular Biology of Activin	258
III. Production and Regulation of Activin and Follistatin	264
IV. Activin Actions	270
V. Conclusions	280
References	281
<b>14. Feedback Regulation by Inhibins A and B of the Pituitary Secretion of Follicle-Stimulating Hormone</b>	<b>299</b>
Yogeshwar Makanji, Craig A. Harrison, and David M. Robertson	
I. Introduction	300
II. Structure, Mechanism of Action, and Function of Inhibins and Activins	301
III. Inhibins A and B Mediated FSH Suppression in Males and Females	305
IV. Understanding the Increased Potency of Inhibin B <i>In Vivo</i> and <i>In Vitro</i>	312
Acknowledgments	317
References	317
<b>15. Activin A in Nonalcoholic Fatty Liver Disease</b>	<b>323</b>
Arne Yndestad, John Willy Haukeland, Tuva B. Dahl, Bente Halvorsen, and Pål Aukrust	
I. Introduction	324
II. Nonalcoholic Fatty Liver Disease	325
III. Activin A in Liver Biology and Pathology	329

---

IV. Activin A in NAFLD	331
V. Conclusion and Future Perspectives	337
References	338
<i>Index</i>	343

# CONTENTS

<i>Contributors</i>	<i>xiii</i>
<i>Preface</i>	<i>xvii</i>
<b>1. Vitamin D Regulation of Immune Function</b>	<b>1</b>
Daniel D. Bikle	
I. Introduction	2
II. 1,25(OH) <sub>2</sub> D Production in Cells of the Immune System: Comparisons to Renal Production	2
III. Role of Vitamin D in the Adaptive Immune Response (Fig. 1.2)	6
IV. Clinical Implications of the Inhibition of the Adaptive Immune Response	9
V. Role of Vitamin D in the Innate Immune Response (Fig. 1.3)	12
VI. Conclusion	15
Acknowledgments	16
References	16
<b>2. Vitamin D and Innate and Adaptive Immunity</b>	<b>23</b>
Martin Hewison	
I. Introduction	24
II. Antibacterial Actions of Vitamin D	25
III. Vitamin D and Antigen Presentation	38
IV. Vitamin D and Adaptive Immunity	42
V. Vitamin D, the Immune System and Human Health	46
VI. Conclusions and Future Directions	49
References	50
<b>3. Dendritic Cells Modified by Vitamin D: Future Immunotherapy for Autoimmune Diseases</b>	<b>63</b>
Ayako Wakatsuki Pedersen, Mogens Helweg Claesson, and Mai-Britt Zocca	
I. Introduction	64
II. DCs and Their Role in the Immune System	64
III. Vitamin D Metabolism in DCs	66
IV. Modulation of DC Function by VDR	67

V. Application of VD <sub>3</sub> -Modulated DCs in Treatment of Autoimmune Diseases	73
VI. Toward Development of Clinically Applicable VD <sub>3</sub> -DCs	74
VII. Conclusions	76
References	77
<b>4. Retinoic Acid, Immunity, and Inflammation</b>	<b>83</b>
Chang H. Kim	
I. Introduction	84
II. Overview of Vitamin A Metabolism and Function	85
III. RA in Regulation of Myeloid Cell Development	86
IV. RA and Effector T Cells	90
V. RA and Regulatory T Cells	92
VI. RA in Regulation of Antibody Responses	93
VII. RA and Tissue Inflammation	94
VIII. Conclusions and Remaining Issues	96
Acknowledgments	96
References	97
<b>5. Vitamin A and Retinoic Acid in the Regulation of B-Cell Development and Antibody Production</b>	<b>103</b>
A. Catharine Ross, Qiuyan Chen, and Yifan Ma	
I. Introduction	104
II. The Vitamin A–Retinoic Acid Signaling System	105
III. RA as a Factor in B-Cell Maturation, Activation, and Proliferation	107
IV. Transcription Factors, CSR, and B-Cell Differentiation Toward the PC Phenotype	111
V. RA as a Factor in Germinal Center Formation	116
References	121
<b>6. Retinoic Acid Production by Intestinal Dendritic Cells</b>	<b>127</b>
Makoto Iwata and Aya Yokota	
I. Introduction	128
II. Backgrounds and General Effects of Vitamin A on Host Defense Systems	129
III. Regulation of Gut-Specific Homing of Lymphocytes by Dendritic Cells	131
IV. Imprinting of Gut-Homing Specificity on Lymphocytes by Retinoic Acid	132
V. Regulation of Functional Differentiation of Lymphocytes by Retinoic Acid-Producing Dendritic Cells	135



VI. Identification of Retinoic Acid-Producing Dendritic Cells	137
VII. The Origin of Retinoic Acid-Producing Dendritic Cells	138
VIII. Induction of Retinoic Acid-Producing Capacity in Dendritic Cells	140
IX. Degradation of Retinoic Acid <i>In Vivo</i> and <i>In Vitro</i>	143
X. Conclusions and Future Directions	144
Acknowledgments	144
References	144
<b>7. Immune Regulator Vitamin A and T Cell Death</b>	<b>153</b>
Nikolai Engedal	
I. Introduction	154
II. Mechanism of Action of Vitamin A	154
III. Cell Death Pathways	156
IV. Forms of T Cell Death	157
V. Regulation of Thymocyte Cell Death by Vitamin A	159
VI. Regulation of Mature T Cell Death by Vitamin A	162
VII. Concluding Discussion and Future Perspectives	170
References	173
<b>8. Vitamin E and Immunity</b>	<b>179</b>
Didem Pekmezci	
I. Introduction	180
II. Definition and Structures of Vitamin E	180
III. Vitamin E Deficiency	181
IV. Vitamin E Requirements and Reference Ranges	183
V. Immunomodulatory Effects of Vitamin E	186
VI. Immunological Use of Vitamin E in Humans	191
VII. Immunological Use of Vitamin E in Animals	196
VIII. Conclusions and Future Aspects	199
Acknowledgments	201
References	201
<b>9. Vitamin D Effects on Lung Immunity and Respiratory Diseases</b>	<b>217</b>
Sif Hansdottir and Martha M. Monick	
I. Introduction	218
II. Lung Immune Functions	218
III. 1,25-Dihydroxyvitamin D is Generated Locally in the Lungs	220
IV. Vitamin D and Lung Infections	225
V. Vitamin D and Obstructive Lung Diseases	229
VI. Conclusions and Future Directions	231
Acknowledgment	232
References	232

<b>10. Maternal Vitamin D During Pregnancy and Its Relation to Immune-Mediated Diseases in the Offspring</b>	<b>239</b>
Erkkola Maijaliisa, Nwaru I. Bright, and Viljakainen T. Heli	
I. Introduction	240
II. Vitamin D	241
III. Vitamin D Status During Pregnancy	247
IV. Dietary Guidelines and Maternal Vitamin D Intake	248
V. Maternal Vitamin D During Pregnancy and Disease Outcomes in the Offspring	250
VI. Conclusions	254
References	255
<b>11. Vitamin D Deficiency and Connective Tissue Disease</b>	<b>261</b>
Eva Zold, Zsolt Barta, and Edit Bodolay	
I. Introduction	262
II. The Immune-Regulative Role of Vitamin D	263
III. Effect of Vitamin D on Innate Immunity	263
IV. Modulation of Adaptive Immunity	265
V. Lymphocytes as Direct Targets for 1,25(OH) <sub>2</sub> D <sub>3</sub>	266
VI. Low Level of Vitamin D and Autoimmune Diseases	268
VII. Causes of Vitamin D Deficiency in Autoimmune Diseases	269
VIII. Vitamin D and Undifferentiated Connective Tissue Disease	270
IX. Vitamin D and Systemic Sclerosis	271
X. Vitamin D and Sjögren's Syndrome	274
XI. Vitamin D and Systemic Lupus Erythematosus	274
XII. Vitamin D and Rheumatoid Arthritis	277
References	279
<b>12. Key Roles of Vitamins A, C, and E in Aflatoxin B<sub>1</sub>-Induced Oxidative Stress</b>	<b>287</b>
Lokman Alpsoy and Mehmet Emir Yalvac	
I. Aflatoxins and AFB <sub>1</sub>	288
II. Molecular Mechanisms of AFB <sub>1</sub> Toxicity	290
III. Inhibition of AFB <sub>1</sub> -Induced Oxidative Stress and Toxicity	291
IV. Interaction Between Dietary Factors and AFB <sub>1</sub> Toxicity	292
V. Vitamin A	294
VI. Vitamin C	295
VII. Vitamin E	296
VIII. Conclusion and Future Remarks	299
Acknowledgment	300
References	300

<b>13. Vitamin D, Vitamin D Receptor, and Cathelicidin in the Treatment of Tuberculosis</b>	<b>307</b>
P. Selvaraj	
I. Introduction	308
II. Vitamin D Metabolism	309
III. Immunomodulatory Role of Vitamin D	309
IV. Cathelicidin and Vitamin D	310
V. Vitamin D Receptor	311
VI. Tuberculosis	313
VII. Vitamin D and Treatment of TB	316
VIII. Conclusion	319
Acknowledgments	320
References	320
<b>14. Vitamin D Endocrine System and the Immune Response in Rheumatic Diseases</b>	<b>327</b>
Maurizio Cutolo, M. Plebani, Yehuda Shoenfeld, Luciano Adorini, and Angela Tincani	
I. Introduction	328
II. Function and Biochemical Measures of Vitamin D	329
III. Vitamin D and Autoimmunity	332
IV. SLE and Other Systemic Autoimmune Diseases	335
V. Vitamin D and Rheumatoid Arthritis	341
VI. Vitamin D and Psoriasis/Psoriatic Arthritis	342
VII. Vitamin D and Overlap Syndromes	343
VIII. Vitamin D Supplementation and VDR Agonists in the Treatment of Rheumatic Diseases	343
IX. Conclusions	346
References	346
<b>15. L-Carnitine and Intestinal Inflammation</b>	<b>353</b>
Geneviève Fortin	
I. L-Carnitine	354
II. Intestinal Inflammation	356
III. L-Carnitine and Intestinal Inflammation	359
IV. Conclusions and Future Directions	363
References	363

<b>16. Vitamin D and Inflammatory Bowel Disease</b>	<b>367</b>
Sandro Ardizzone, Andrea Cassinotti, Maurizio Bevilacqua, Mario Clerici, and Gabriele Bianchi Porro	
I. Introduction	368
II. Conclusions	375
References	375
<b>17. Vitamin D Deficiency and Chronic Obstructive Pulmonary Disease: A Vicious Circle</b>	<b>379</b>
Wim Janssens, Chantal Mathieu, Steven Boonen, and Marc Decramer	
I. Introduction	380
II. Prevalence and Determinants of Vitamin D Deficiency in COPD	382
III. COPD and Osteoporosis: Role for Vitamin D	385
IV. Airway and Systemic Inflammation in COPD: Link with Vitamin D Pathway	388
V. Conclusion	393
Acknowledgments	393
References	393
<b>18. Vitamin D as a T-cell Modulator in Multiple Sclerosis</b>	<b>401</b>
Joost Smolders and Jan Damoiseaux	
I. Introduction	402
II. Multiple Sclerosis	402
III. Vitamin D	404
IV. Vitamin D and T-cell Regulation in MS	408
V. Concluding Remarks	421
References	422
<b>19. Vitamin D in Solid Organ Transplantation with Special Emphasis on Kidney Transplantation</b>	<b>429</b>
Ursula Thiem and Kyra Borchardt	
I. Vitamin D	430
II. Vitamin D and the Immune System	435
III. Vitamin D in Kidney Transplant Recipients	444
IV. Vitamin D in Other Transplant Recipients	455
V. Conclusion and Future Directions	456
References	457
<i>Index</i>	<b>469</b>

# CONTENTS

<i>Contributors</i>	xv
<i>Preface</i>	xxi
<b>1. Factors Regulating Pluripotency and Differentiation in Early Mammalian Embryos and Embryo-derived Stem Cells</b>	<b>1</b>
Aneta Suwinska and Maria A. Ciemerych	
I. Introduction	2
II. From Totipotency to Pluripotency	3
III. Inner Cell Mass (ICM): Pluripotent Cells in the Mammalian Embryo	4
IV. Embryo-Derived Stem Cells	15
V. Transcriptional Regulators of Pluripotency in Embryo-Derived Stem Cells	17
VI. Extrinsic Factors and Signaling Pathways Regulating Pluripotency and Differentiation	19
VII. Conclusions	26
Acknowledgments	26
References	27
<b>2. Molecular Mediators of Mesenchymal Stem Cell Biology</b>	<b>39</b>
Maria P. Alfaro, Sarika Saraswati, and Pampee P. Young	
I. Introduction	40
II. Mesenchymal Stem Cells	40
III. Differentiation of MSCs	41
IV. Self-Renewal	41
V. MSC Therapy	42
VI. Immunomodulatory Properties	44
VII. MI Therapy	44
VIII. Molecular Mediators of MSC Biology	45
IX. Enhancing MSC Survival in the Wound	50
X. Secreted Frizzled-Related Proteins	50
XI. Mediating MSC Self-Renewal	51
XII. Conclusions	52
References	53

<b>3. Insulin and Germline Proliferation in <i>Caenorhabditis elegans</i></b>	<b>61</b>
E. Jane Albert Hubbard	
I. Germline Proliferation in <i>C. elegans</i> : A Model for Developmental, Physiological, and Environmental Control of Cell Proliferation	62
II. <i>C. elegans</i> Germline Development	63
III. The <i>C. elegans</i> Germ line “Proliferation Versus Differentiation” Decision Is Mediated from the Soma to the Germ line by a Conserved Notch Signaling Pathway	64
IV. Evidence for Notch-Independent Soma-Germ line Signaling Mechanisms That Modulate Germline Proliferation	65
V. A Counter-Intuitive Assay to Identify Potential Notch-Independent Mechanisms That Promote the Expansion of the Larval Germline Progenitor Pool	66
VI. Identification of the Insulin/IGF-Like Receptor (IIR) Pathway in Germline Proliferation	68
VII. IIR Signaling in <i>C. elegans</i>	69
VIII. Insulin Signaling Promotes the Larval Germline Cell Division Cycle	70
IX. <i>C. elegans</i> Insulins	71
X. Many Target Tissues for IIR Signaling	71
XI. Other Germline Roles for the IIR Pathway	73
XII. IIR Role in Larval Germline Proliferation: A Reproductive Timing and Lifespan Connection?	74
XIII. A Current Model and Future Directions	74
Acknowledgments	76
References	76
<b>4. Generating Mature <math>\beta</math>-Cells from Embryonic Stem Cells: Strategies for Late-Stage Differentiation</b>	<b>79</b>
Spyridon Champeris Tsaniras	
I. Introduction	79
II. Signaling Pathways in $\beta$ -Cell Differentiation	81
III. Summary and Conclusions	86
Acknowledgments	87
References	87
<b>5. Activation and Regulation of Reserve Liver Progenitor Cells</b>	<b>93</b>
D. Hunter Best and William B. Coleman	
I. Introduction	94
II. Activation and Regulation of Mature Hepatocytes in Normal Liver Regeneration	94
III. Reserve Liver Progenitor Cells	97

IV. Hierarchical Responses in Liver Disease and Regeneration	102
References	103
<b>6. Adult Cardiac-Derived Stem Cells: Differentiation and Survival Regulators</b>	<b>111</b>
Nanako Kawaguchi	
I. Introduction	112
II. c-kit-Positive Cardiac Cells	113
III. Conclusions and Future Prospects	121
Acknowledgments	121
References	121
<b>7. TGF-<math>\beta</math>1 Regulates Differentiation of Bone Marrow Mesenchymal Stem Cells</b>	<b>127</b>
Longmei Zhao and Basil M. Hantash	
I. Bone Marrow Mesenchymal Stem Cells	128
II. The Role of TGF- $\beta$ 1 in Differentiation of Bone Marrow MSCs	131
III. Summary	137
Acknowledgments	137
References	137
<b>8. Maternal Intake of Folic Acid and Neural Crest Stem Cells</b>	<b>143</b>
Chandra S. Mayanil, Shunsuke Ichi, Barbara-Mania Farnell, Vanda Boshnjaku, Tadanori Tomita, and David G. McLone	
I. Introduction	144
II. Role of FA in Human Health	145
III. Mouse Models of NTD	148
IV. Neural Crest Development and Neural Crest Stem Cells	149
V. Role of FA in Neural Crest Development	151
VI. Folate Nonresponsive Genetic Mouse Models	162
VII. Conclusions and Future Directions	162
Acknowledgments	163
References	163
<b>9. Modulation of the Generation of Dopaminergic Neurons from Human Neural Stem Cells by Bcl-X<sub>L</sub>: Mechanisms of Action</b>	<b>175</b>
Alberto Martínez-Serrano, Claudia G. Castillo, Elise T. Courtois, Elisa García-García, and Isabel Liste	
I. Introduction	176
II. Sources of Human DAN for Cell Replacement in PD	178

III. Epigenetic Cues and Genetic Manipulations to Improve hNSCs Differentiation Toward the A9 DA Phenotype	185
IV. Concluding Remarks	197
Acknowledgments	198
References	198
<b>10. Glucocorticoid Hedgehog Agonists in Neurogenesis</b>	<b>207</b>
Jiangbo Wang, Larry S. Barak, Robert A. Mook, and Wei Chen	
I. Introduction	208
II. Select Glucocorticoids as Smoothened Agonists: Potential Effects for Neurogenesis	209
III. Mechanism of Action	210
IV. Structure–Activity Relationships (SAR) of Glucocorticoid Smoothened Agonists	211
V. Conclusion	212
References	214
<b>11. Effect of Progesterone on Human Mesenchymal Stem Cells</b>	<b>217</b>
Dobroslav S. Kyurkchiev, Ekaterina Ivanova-Todorova, and Stanimir D. Kyurkchiev	
I. Introduction	218
II. Biological Roles of Progesterone	218
III. Mesenchymal Stem Cells	222
IV. Multipotent MSCs in Human Endometrium	224
V. Interaction Between Progesterone and MSCs	226
VI. Conclusions and Future Directions	231
Acknowledgments	231
References	231
<b>12. Regulation of Muscle Stem Cells Activation: The Role of Growth Factors and Extracellular Matrix</b>	<b>239</b>
Edyta Brzoska, Maria A. Ciemerych, Marta Przewozniak, and Małgorzata Zimowska	
I. Cells Participating in Muscle Growth and Repair: Mechanisms of Activation	240
II. The Unique Ability of Skeletal Muscles to Regenerate	246
III. Muscle Stem Cells Activation: The Importance of Satellite Cell Niche	249
IV. The Interactions with ECM	252
V. Growth Factors Regulating Activation of Satellite Cells: The Case of HGF	255
VI. Other ECM-bound Growth Factors Regulating Myoblast Proliferation and Differentiation	258



VII. Concluding Remarks	260
Acknowledgments	261
References	261
<b>13. Thymosins and Muscle Regeneration</b>	<b>277</b>
Takahiko Hara	
I. Introduction	278
II. Basic Properties of Thymosins	278
III. Physiological Activities of T $\beta_4$	281
IV. Roles of T $\beta_4$ in Skin Tissue Regeneration	282
V. Roles of T $\beta_4$ in Heart Regeneration	282
VI. Roles of T $\beta_4$ in Skeletal Muscle Regeneration	283
VII. Signaling Mechanism Involved in the Chemotactic Activity of T $\beta_4$	285
VIII. Concluding Remarks	285
References	286
<b>14. MicroRNAs and Mesenchymal Stem Cells</b>	<b>291</b>
Federica Collino, Stefania Bruno, Maria Chiara Deregibus, Ciro Tetta, and Giovanni Camussi	
I. Introduction	292
II. MicroRNAs	293
III. Mesenchymal Stem Cells	296
IV. miRNAs and Stem Cells	296
V. Role of miRNAs in MSC Differentiation	299
VI. The Role of miRNAs in Cell-to-Cell Communication	306
VII. Conclusions	312
Acknowledgments	312
References	312
<b>15. MicroRNA and Vascular Smooth Muscle Cells</b>	<b>321</b>
Changqing Xie, Jifeng Zhang, and Y. Eugene Chen	
I. Introduction	322
II. miRNA Biogenesis and Mechanism	323
III. miRNA and VSMC Differentiation	325
IV. miRNA and VSMC Phenotypic Switch	326
V. miRNA and VSMC Neointima Hyperplasia	329
VI. miRNA and VSMC-Related Diseases	330
VII. Prospective Application of miRNAs as Therapeutics for Vascular Disease	333
Acknowledgments	334
References	334

<b>16. Transforming Growth Factor-Beta Superfamily in Mouse Embryonic Stem Cell Self-Renewal</b>	<b>341</b>
Katherine E. Galvin-Burgess and Jay L. Vivian	
I. Introduction	342
II. Overview of TGF-Beta-Related Signaling	343
III. ES Cell Regulation by the BMP Pathway	347
IV. ES Cell Regulation by the Nodal Pathway	350
V. Interactions of TGF-Beta Signaling with Other Pluripotency Pathways	354
VI. TGF-Beta Signaling in Other Pluripotent Cells	354
VII. Conclusions and Future Directions	358
Acknowledgment	359
References	359
<b>17. The Biology of HIF<math>\alpha</math> Proteins in Cell Differentiation and Disease</b>	<b>367</b>
Inmaculada Royo González, Victoria Moreno-Manzano, Francisco Javier Rodríguez-Jimenez, Pilar Sepúlveda, and José-María Sánchez-Puelles	
I. Introduction	368
II. HIF and Cancer	369
III. HIF and Stem	370
IV. HIF and Neurodegenerative Diseases	372
V. HIFs in Cardiac Ischemic Diseases	373
VI. HIFs as Target	374
VII. Conclusion	375
References	375
<b>18. Regulatory Role of Klf5 in Early Mouse Development and in Embryonic Stem Cells</b>	<b>381</b>
Silvia Parisi and Tommaso Russo	
I. Klf5: A Krüppel-Like Transcription Factor	382
II. Multiple Functions of Klf5	382
III. Klf5 in Reprogramming	383
IV. Gene Expression Network for the Maintenance of ESC Pluripotent State	384
V. Klf5 Function in ESCs	385
VI. Klf5 Role in Early Embryonic Development	387
VII. Klf5 Targets	390
VIII. Klf5 Connection to the Core Pluripotency Network	391
IX. Conclusions	392
Acknowledgments	392
References	393

---

<b>19. Bam and Bgcn in <i>Drosophila</i> Germline Stem Cell Differentiation</b>	<b>399</b>
Sreejith Perinthottathil and Changsoo Kim	
I. Introduction	400
II. Bam Repression of Stem Cell Maintenance Factors	402
III. Conclusion	409
Acknowledgments	412
References	413
<b>20. The Effects of Mechanical Loading on Mesenchymal Stem Cell Differentiation and Matrix Production</b>	<b>417</b>
Robin M. Delaine-Smith and Gwendolen C. Reilly	
I. Introduction	418
II. Mesenchymal Stem Cells	420
III. Mechanical Loading	427
IV. Experimental Results	433
V. Conclusions and Future Directions	466
Acknowledgments	469
References	469
<i>Index</i>	<i>481</i>